A

Farrugia, D. C., Ford, H. E. R., Cunningham, D., Danenberg, K. D., Danenberg, P. V., Brabender, J., McVicar, A. D., Aherne, G. W., Hardcastle, A., McCarthy, K., Jackman, A. L. (2003) Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. CLINICAL CANCER RESEARCH, 9 (2). pp. 792-801. ISSN 1078-0432

Muls, A. C., Klimova, K., Andreyev, H. J. N. (2018) Clinical decision-making in managing changes in gastrointestinal function following cancer therapies: Is experience enough? EUROPEAN JOURNAL OF CANCER CARE, 27 (1). p. 4. ISSN 0961-5423

Taylor, S., Demeyin, W., Muls, A., Ferguson, C., Farnell, D. J. J., Cohen, D., Andreyev, J., Green, J., Smith, L., Ahmedzai, S., Pickett, S., Nelson, A., Staffurth, J. (2016) Improving the well-being of men by Evaluating and Addressing the Gastrointestinal Late Effects (EAGLE) of radical treatment for prostate cancer: study protocol for a mixed-method implementation project. Bmj Open, 6 (10). ISSN 2044-6055

Lawrie, T. A., Green, J. T., Beresford, M., Wedlake, L., Burden, S., Davidson, S. E., Lal, S., Henson, C. C., Andreyev, H. J. N. (2018) Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers (Review). COCHRANE DATABASE OF SYSTEMATIC REVIEWS (1). ISSN 1469-493X

Muls, A. C., Lalji, A., Marshall, C., Butler, L., Shaw, C., Vyoral, S., Mohammed, K., Andreyev, H. J. N. (2016) The holistic management of consequences of cancer treatment by a gastrointestinal and nutrition team: a financially viable approach to an enormous problem? CLINICAL MEDICINE, 16 (3). pp. 240-246. ISSN 1470-2118

Chong, I. Y., Cunningham, D., Barber, L. J., Campbell, J., Chen, L., Kozarewa, I., Fenwick, K., Assiotis, I., Guettler, S., Garcia-Murillas, I., Awan, S., Lambros, M., Starling, N., Wotherspoon, A., Stamp, G., Gonzalez-de-Castro, D., Benson, M., Chau, I., Hulkki, S., Nohadani, M., Eltahir, Z., Lemnrau, A., Orr, N., Rao, S., Lord, C. J., Ashworth, A. (2013) The genomic landscape of oesophagogastric junctional adenocarcinoma. JOURNAL OF PATHOLOGY, 231 (3). pp. 301-310. ISSN 0022-3417

Hewish, M., Martin, S. A., Elliott, R., Cunningham, D., Lord, C. J., Ashworth, A. (2013) Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress. BRITISH JOURNAL OF CANCER, 108 (4). pp. 983-992. ISSN 0007-0920

Wetterskog, D., Shiu, K. K., Chong, I., Meijer, T., Mackay, A., Lambros, M., Cunningham, D., Reis-Filho, J. S., Lord, C. J., Ashworth, A. (2014) Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers. ONCOGENE, 33 (8). pp. 966-976. ISSN 0950-9232

B

Siddiqui, M., Nagtegaal, I., Santiago, I., Knijn, N., Berho, M., Mirnezami, A., Rao, S., Brown, G. (2018) Session 2: What causes liver metastases - lymph nodes or is it something else? COLORECTAL DISEASE, 20. pp. 39-42. ISSN 1462-8910

Brown, G., Daniels, I. R., Heald, R. J., Quirke, P., Blomqvist, L., Sebag-Montefiore, D., Moran, B. J., Holm, T., Strassbourg, J., Peppercorn, P. D., Fisher, S. E., Mason, B., MERCURY Study Grp, [Group Author] (2006) Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BRITISH MEDICAL JOURNAL, 333 (7572). pp. 779-782. ISSN 0007-1447

Shihab, O. C., Taylor, F., Bees, N., Blake, H., Jeyadevan, N., Bleehen, R., Blomqvist, L., Creagh, M., George, C., Guthrie, A., Massouh, H., Peppercorn, D., Moran, B. J., Heald, R. J., Quirke, P., Tekkis, P., Brown, G. (2011) Relevance of magnetic resonance imaging-detected pelvic sidewall lymph node involvement in rectal cancer. BRITISH JOURNAL OF SURGERY, 98 (12). pp. 1798-1804. ISSN 0007-1323

Patel, U. B., Blomqvist, L., Chau, I., Nicholls, J., Brown, G. (2018) Session 3: Beyond TME and radiotherapy MRI evaluation of rectal cancer treatment response. COLORECTAL DISEASE, 20. pp. 76-81. ISSN 1462-8910

Starling, N., Hawkes, E. A., Chau, I., Watkins, D., Thomas, J., Webb, J., Brown, G., Thomas, K., Barbachano, Y., Oates, J., Cunningham, D. (2012) A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. ANNALS OF ONCOLOGY, 23 (4). pp. 942-947. ISSN 0923-7534

Patel, U. B., Cervantes, A., Fernandez-Martos, C., Sclafani, F., Cunningham, D., Nilsson, P., Brown, G. (2018) Session 2: Are we ready for primary chemotherapy in rectal cancer: who, when, why? COLORECTAL DISEASE, 20. pp. 56-60. ISSN 1462-8910

Brown, G., Drury, A. E., Cunningham, D., Husband, J. E. S. (2003) CT detection of hydronephrosis in resected colorectal cancer: a predictor of recurrent disease. CLINICAL RADIOLOGY, 58 (2). pp. 137-142. ISSN 0009-9260

Chau, I., Brown, G., Cunningham, D., Tait, D., Wotherspoon, A., Norman, A. R., Tebbutt, N., Hill, M., Ross, P. J., Massey, A., Oates, J. (2006) Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 24 (4). pp. 668-674. ISSN 0732-183X

Assersohn, L., Brown, G., Cunningham, D., Ward, C., Oates, J., Waters, J. S., Hill, M. E., Norman, A. R. (2004) Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. ANNALS OF ONCOLOGY, 15 (1). pp. 64-69. ISSN 0923-7534

Riddell, A. M., Hillier, J., Brown, G., King, D. M., Wotherspoon, A. C., Thompson, J. N., Cunningham, D., Allum, W. H. (2006) Potential of surface-coil MRI for staging of esophageal cancer. AMERICAN JOURNAL OF ROENTGENOLOGY, 187 (5). pp. 1280-1287. ISSN 0361-803X

Chau, I., Allen, M., Cunningham, D., Tait, D., Brown, G., Hill, M., Sumpter, K., Rhodes, A., Wotherspoon, A., Norman, A. R., Hill, A., Massey, A., Prior, Y. (2003) Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. BRITISH JOURNAL OF CANCER, 88 (7). pp. 1017-1024. ISSN 0007-0920

Chau, I., Kelleher, M. T., Cunningham, D., Norman, A., Wotherspoon, A., Trott, P., Rhys-Evans, P. G., Querci-Della Rovere, Q., Brown, G., Allen, M., Waters, J. S., Haque, S., Murray, T., Bishop, L. (2003) Rapid access multidisciplinary lymph node diagnostic clinic: analysis of 550 patients. BRITISH JOURNAL OF CANCER, 88 (3). pp. 354-361. ISSN 0007-0920

Evans, J., Tait, D., Swift, I., Pennert, K., Tekkis, P., Wotherspoon, A., Chau, I., Cunningham, D., Brown, G. (2011) Timing of Surgery Following Preoperative Therapy in Rectal Cancer: The Need for a Prospective Randomized Trial? DISEASES OF THE COLON & RECTUM, 54 (10). pp. 1251-1259. ISSN 0012-3706

C

Muro, K., Cho, J. Y., Bodoky, G., Goswami, C., Chao, Y., dos Santos, L. V., Shimada, Y., Topuzov, E., Van Cutsem, E., Tabernero, J., Zalcberg, J., Chau, I., Cascinu, S., Cheng, R., Hsu, Y., Emig, M., Orlando, M., Fuchs, C. (2018) Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 33 (4). pp. 814-824. ISSN 0815-9319

Chau, I., Park, J. O., Ryoo, B. Y., Yen, C. J., Poon, R., Pastorelli, D., Blanc, J. F., Kudo, M., Pfiffer, T., Hatano, E., Chung, H. C., Kopeckova, K., Phelip, J. M., Brandi, G., Ohkawa, S., Li, C. P., Okusaka, T., Hsu, Y. Z., Abada, P. B., Zhu, A. X. (2018) Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. BRITISH JOURNAL OF CANCER, 119 (1). pp. 19-26. ISSN 0007-0920

Fuchs, C. S., Tabernero, J., Tomasek, J., Chau, I., Melichar, B., Safran, H., Tehfe, M. A., Filip, D., Topuzov, E., Schlittler, L., Udrea, A. A., Campbell, W., Brincat, S., Emig, M., Melemed, S. A., Hozak, R. R., Ferry, D., Caldwell, C. W., Ajani, J. A. (2016) Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. BRITISH JOURNAL OF CANCER, 115 (8). pp. 974-982. ISSN 0007-0920

Chau, I. (2017) Checkpoint inhibition: an ATTRACTION in advanced gastric cancer? LANCET, 390 (10111). pp. 2418-2419. ISSN 0140-6736

Chau, I. (2017) Clinical Development of PD-1/ PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes. CLINICAL CANCER RESEARCH, 23 (20). pp. 6002-6011. ISSN 1078-0432

Davidson, M., Chau, I. (2016) Colorectal cancer trial endpoints: time for dynamic thinking? LANCET ONCOLOGY, 17 (10). pp. 1345-1347. ISSN 1470-2045

Segelov, E., Lordick, F., Goldstein, D., Chantrill, L. A., Croagh, D., Lawrence, B., Arnold, D., Chau, I., Obermannova, R., Price, T. J. (2017) Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. EXPERT REVIEW OF ANTICANCER THERAPY, 17 (10). pp. 951-964. ISSN 1473-7140

Anandappa, G., Chau, I. (2017) Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 31 (3). pp. 529-544. ISSN 0889-8588

Petty, R. D., Dahle-Smith, A., Stevenson, D. A. J., Osborne, A., Massie, D., Clark, C., Murray, G. I., Dutton, S. J., Roberts, C., Chong, I. Y., Mansoor, W., Thompson, J., Harrison, M., Chatterjee, A., Falk, S. J., Elyan, S., Garcia-Alonso, A., Fyfe, D. W., Wadsley, J., Chau, I., Ferry, D. R., Miedzybrodzka, Z. (2017) Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. JOURNAL OF CLINICAL ONCOLOGY, 35 (20). pp. 2279-2287. ISSN 0732-183X

Vogel, A., Cervantes, A., Chau, I., Daniele, B., Llovet, J., Meyer, T., Nault, J. C., Neumann, U., Ricke, J., Sangro, B., Schirmacher, P., Verslype, C., Zech, C. J., Arnold, D., Martinelli, E., Comm, Esmo Guidelines (2018) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, 29. pp. 238-255. ISSN 0923-7534

Bruengger, A. A. S., Wechalekar, K., Khattar, R., Rosen, S. D., Robertus, J. L., Chau, I., Morganstein, D., Rosendahl, U., Lyon, A., Mohiaddin, R. (2017) Histologically Proven Myocardial Carcinoid Metastases: The Value of Multimodality Imaging. CANADIAN JOURNAL OF CARDIOLOGY, 33 (10). p. 4. ISSN 0828-282X

Davidson, M., Chau, I. (2016) Immunotherapy for oesophagogastric cancer. EXPERT OPINION ON BIOLOGICAL THERAPY, 16 (10). pp. 1197-1207. ISSN 1471-2598

Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., Hallmeyer, S., Chakrabarty, J. H., Leighl, N. B., Mammen, J. S., McDermott, D. F., Naing, A., Nastoupil, L. J., Phillips, T., Porter, L. D., Puzanov, I., Reichner, C. A., Santomasso, B. D., Seigel, C., Spira, A., Suarez-Almazor, M. E., Wang, Y. H., Weber, J. S., Wolchok, J. D., Thompson, J. A., Natl Comprehensive Canc, Network (2018) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. JOURNAL OF CLINICAL ONCOLOGY, 36 (17). pp. 1714-1768. ISSN 0732-183X

Arnold, D., Fuchs, C. S., Tabernero, J., Ohtsu, A., Zhu, A. X., Garon, E. B., Mackey, J. R., Paz-Ares, L., Baron, A. D., Okusaka, T., Yoshino, T., Yoon, H. H., Das, M., Ferry, D., Zhang, Y., Lin, Y., Binder, P., Sashegyi, A., Chau, I. (2017) Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. ANNALS OF ONCOLOGY, 28 (12). pp. 2932-2942. ISSN 0923-7534

Davidson, M., Chau, I. (2018) Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches. EXPERT REVIEW OF ANTICANCER THERAPY, 18 (4). pp. 327-338. ISSN 1473-7140

Cafferkey, C., Chau, I. (2016) Novel STAT 3 inhibitors for treating gastric cancer. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 25 (9). pp. 1023-1031. ISSN 1354-3784

Fuchs, C. S., Muro, K., Tomasek, J., Van Cutsem, E., Cho, J. Y., Oh, S. C., Safran, H., Bodoky, G., Chau, I., Shimada, Y., Al-Batran, S. E., Passalacqua, R., Ohtsu, A., Emig, M., Ferry, D., Chandrawansa, K., Hsu, Y., Sashegyi, A., Liepa, A. M., Wilke, H. (2017) Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. JOURNAL OF GASTRIC CANCER, 17 (2). pp. 132-144. ISSN 2093-582X

Zhu, A. X., Baron, A. D., Malfertheiner, P., Kudo, M., Kawazoe, S., Pezet, D., Weissinger, F., Brandi, G., Barone, C. A., Okusaka, T., Wada, Y., Park, J. O., Ryoo, B. Y., Cho, J. Y., Chung, H. C., Li, C. P., Yen, C. J., Lee, K. D., Chang, S. C., Yang, L., Abada, P. B., Chau, I. (2017) Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Analysis of REACH Trial Results by Child-Pugh Score. Jama Oncology, 3 (2). pp. 235-243. ISSN 2374-2445

Chau, I., Peck-Radosavljevic, M., Borg, C., Malfertheiner, P., Seitz, J. F., Park, J. O., Ryoo, B. Y., Yen, C. J., Kudo, M., Poon, R., Pastorelli, D., Blanc, J. F., Chung, H. C., Baron, A. D., Okusaka, T., Bowman, L., Cui, Z. L., Girvan, A. C., Abada, P. B., Yang, L., Zhu, A. X. (2017) Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. EUROPEAN JOURNAL OF CANCER, 81. pp. 17-25. ISSN 0959-8049

Chau, I., Peck-Radosavljevic, M., Borg, C., Malfertheiner, P., Seitz, J. F., Park, J. O., Ryoo, B. Y., Yen, C. J., Kudo, M., Poon, R., Pastorelli, D., Blanc, J. F., Chung, H. C., Baron, A. D., Okusaka, T., Bowman, L., Cui, Z. L., Girvan, A. C., Abada, P. B., Yang, L., Zhu, A. X. (2018) Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study (vol 81, pg 17, 2017). [Correction]

Riess, H., Ay, C., Bauersachs, R., Becattini, C., Beyer-Westendorf, J., Cajfinger, F., Chau, I., Cohen, A. T., Khorana, A. A., Maraveyas, A., Renni, M., Young, A. M. (2018) Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. ONCOLOGIST, 23 (7). pp. 822-839. ISSN 1083-7159

Diamond, E. L., Subbiah, V., Lockhart, A. C., Blay, J. Y., Puzanov, I., Chau, I., Raje, N. S., Wolf, J., Erinjeri, J. P., Torrisi, J., Lacouture, M., Elez, E., Martinez-Valle, F., Durham, B., Arcila, M. E., Ulaner, G., Abdel-Wahab, O., Pitcher, B., Makrutzki, M., Riehl, T., Baselga, J., Hyman, D. M. (2018) Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA ONCOLOGY, 4 (3). pp. 384-388. ISSN 2374-2437

Andreyev, J., Ross, P., Donnellan, C., Lennan, E., Leonard, P., Waters, C., Wedlake, L., Bridgewater, J., Glynne-Jones, R., Allum, W., Chau, I., Wilson, R., Ferry, D. (2014) Guidance on the management of diarrhoea during cancer chemotherapy. LANCET ONCOLOGY, 15 (10). E447-E460. ISSN 1470-2045

Bystricky, B., Chau, I. (2011) Patupilone in cancer treatment. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 20 (1). pp. 107-117. ISSN 1354-3784

Young, K., Smyth, E., Chau, I. (2015) Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 8 (6). pp. 373-383. ISSN 1756-283X

Moorcraft, S. Y., Begum, R., Cunningham, D., Peckitt, C., Baratelli, C., Gillbanks, A., Rogers, P., Nwokorie, V., Chau, I., Watkins, D., Starling, N. (2017) Attitudes of Patients With Gastrointestinal Cancers Toward Research Biopsies. CLINICAL COLORECTAL CANCER, 16 (3). E181-E189. ISSN 1533-0028

Kuhnl, A., Cunningham, D., Chau, I. (2017) Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma. CANCER TREATMENT REVIEWS, 59. pp. 132-137. ISSN 0305-7372

Chau, I., Cunningham, D. (2002) Adjuvant therapy in colon cancer: current status and future directions cancer. CANCER TREATMENT REVIEWS, 28 (5). pp. 223-236. ISSN 0305-7372

Okines, A., Chau, I., Cunningham, D. (2008) CAPECITABINE IN GASTRIC CANCER. DRUGS OF TODAY, 44 (8). pp. 629-640. ISSN 0025-7656

Tarazona, N., Smyth, E. C., Peckit, C., Chau, I., Watkins, D., Rao, S., Starling, N., Cunningham, D. (2016) Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma. Therapeutic Advances in Medical Oncology, 8 (2). pp. 104-112. ISSN 1758-8340

Waddell, T., Chau, I., Cunningham, D., Gonzalez, D., Frances, A., Okines, C., Wotherspoon, A., Saffery, C., Middleton, G., Wadsley, J., Ferry, D., Mansoor, W., Crosby, T., Coxon, F., Smith, D., Waters, J., Iveson, T., Falk, S., Slater, S., Peckitt, C., Barbachano, Y. (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. LANCET ONCOLOGY, 14 (6). pp. 481-489. ISSN 1470-2045

Chau, I., Watkins, D., Cunningham, D. (2002) Gemcitabine and its combinations in the treatment of malignant lymphoma. CLINICAL LYMPHOMA, 3 (2). pp. 97-104. ISSN 1526-9655

Strimpakos, A. S., Cunningham, D., Mikropoulos, C., Petkar, I., Barbachano, Y., Chau, I. (2010) The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. ANNALS OF ONCOLOGY, 21 (5). pp. 1013-1019. ISSN 0923-7534

Barton, S., Peckitt, C., Sclafani, F., Cunningham, D., Chau, I. (2015) The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology. EUROPEAN JOURNAL OF CANCER, 51 (18). pp. 2732-2739. ISSN 0959-8049

Young, K., Iyer, R., Morganstein, D., Chau, I., Cunningham, D., Starling, N. (2015) Pancreatic neuroendocrine tumors: a review. FUTURE ONCOLOGY, 11 (5). pp. 853-864. ISSN 1479-6694

Sclafani, F., Smyth, E., Cunningham, D., Chau, I., Turner, A., Watkins, D. (2014) A Pilot Study Assessing the Incidence and Clinical Significance of Circulating Tumor Cells in Esophagogastric Cancers. CLINICAL COLORECTAL CANCER, 13 (2). pp. 94-99. ISSN 1533-0028

Jain, V. K., Cunningham, D., Chau, I. (2012) Preoperative and Postoperative Chemotherapy for Gastric Cancer. SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 21 (1). 99-+. ISSN 1055-3207

Khan, K., Peckitt, C., Sclafani, F., Watkins, D., Rao, S., Starling, N., Jain, V., Trivedi, S., Stanway, S., Cunningham, D., Chau, I. (2015) Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience. BMC CANCER, 15. ISSN 1471-2407

Okines, A. F. C., Asghar, U., Cunningham, D., Ashley, S., Ashton, J., Jackson, K., Hawkes, E., Chau, I. (2010) Rechallenge with Platinum plus Fluoropyrimidine +/- Epirubicin in Patients with Oesophagogastric Cancer. ONCOLOGY, 79 (1-2). pp. 150-158. ISSN 0030-2414

Okines, A. F. C., Dewdney, A., Chau, I., Rao, S., Cunningham, D. (2010) Trastuzumab for gastric cancer treatment. LANCET, 376 (9754). p. 1736. ISSN 0140-6736

Starling, N., Watkins, D., Cunningham, D., Thomas, J., Webb, J., Brown, G., Thomas, K., Oates, J., Chau, I. (2009) Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer. JOURNAL OF CLINICAL ONCOLOGY, 27 (33). pp. 5499-5505. ISSN 0732-183X

Wong, R., Cunningham, D., Barbachano, Y., Saffery, C., Valle, J., Hickish, T., Mudan, S., Brown, G., Khan, A., Wotherspoon, A., Strimpakos, A. S., Thomas, J., Compton, S., Chua, Y. J., Chau, I. (2011) A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. ANNALS OF ONCOLOGY, 22 (9). pp. 2042-2048. ISSN 0923-7534

Baird, R., Biondo, A., Chhaya, V., McLachlan, J., Karpathakis, A., Rahman, S., Barbachano, Y., Cunningham, D., Chau, I. (2011) Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. BRITISH JOURNAL OF CANCER, 104 (1). pp. 43-50. ISSN 0007-0920

Moorcraft, S. Y., Jones, T., Walker, B. A., Ladas, G., Kalaitzaki, E., Yuan, L. N., Begum, R., Eltahir, Z., Wotherspoon, A., Montero-Fernandez, A., Mendes, L. S. T., de Castro, D. G., Wilson, S. H., Proszek, P., To, Y. M., Hawkes, E., Roy, A., Cunningham, D., Rao, S., Watkins, D., Starling, N., Bowcock, A. M., Chau, I. (2017) Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. ONCOTARGET, 8 (39). pp. 64999-65008. ISSN 1949-2553

Khan, K., Cunningham, D., Peckitt, C., Barton, S., Tait, D., Hawkins, M., Watkins, D., Starling, N., Rao, S., Begum, R., Thomas, J., Oates, J., Guzzardo, V., Fassan, M., Braconi, C., Chau, I. (2016) miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget, 7 (11). pp. 12672-12681. ISSN 1949-2553

Lote, H., Valeri, N., Chau, I. (2018) HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer4. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 10 (7). pp. 159-171. ISSN 1948-5204

Andreyev, H. J. N., Ross, P. J., Cunningham, D., Clarke, P. A. (2001) Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma. GUT, 48 (2). pp. 230-237. ISSN 0017-5749

Andreyev, H. J. N., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., Beranek, M., Jandik, P., Benamouzig, R., Jullian, E., Laurent-Puig, P., Olschwang, S., Muller, O., Hoffmann, I., Rabes, H. M., Zietz, C., Troungos, C., Valavanis, C., Yuen, S. T., Ho, J. W. C., Croke, C. T., O'Donoghue, D. P., Giaretti, W., Rapallo, A., Russo, A., Bazan, V., Tanaka, M., Omura, K., Azuma, T., Ohkusa, T., Fujimori, T., Ono, Y., Pauly, M., Faber, C., Glaesener, R., de Goeij, A. F. P. M., Arends, J. W., Andersen, S. N., Lovig, T., Breivik, J., Gaudernack, G., Clausen, O. P. F., De Angelis, P., Meling, G. I., Rognum, T. O., Smith, R., Goh, H. S., Font, A., Rosell, R., Sun, X. F., Zhang, H., Benhattar, J., Losi, L., Lee, J. Q., Wang, S. T., Clarke, P. A., Bell, S., Quirke, P., Bubb, V. J., Piris, J., Cruickshank, N. R., Morton, D., Fox, J. C., Al-Mulla, F., Lees, N., Hall, C. N., Snary, D., Wilkinson, K., Dillon, D., Costa, J., Pricolo, V. E., Finkelstein, S. D., Thebo, J. S., Senagore, A. J., Halter, S. A., Wadler, S., Malik, S., Krtolica, K., Urosevic, N. (2001) Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. BRITISH JOURNAL OF CANCER, 85 (5). pp. 692-696. ISSN 0007-0920

Andreyev, H. J. N., Benamouzig, R., Beranek, M., Clarke, P., Cunningham, D., Norman, A. R., Giaretti, W., de Goeij, A. F. P. M., Iacopetta, B. J,. Jullian, E., Krtolica, K., Lee, J. Q., Wang, S. T., Lees, N., Al-Mulla, F., Muller, O., Pauly, M., Pricolo, V., Russo, A., Troungos, C., Urosevic, N., Ward, R. (2003) Mutant K-ras2 in serum. GUT, 52 (6). pp. 915-916. ISSN 0017-5749

Iveson, T. J., Kerr, R. S., Saunders, M. P., Cassidy, J., Hollander, N. H., Tabernero, J., Haydon, A., Glimelius, B., Harkin, A., Allan, K., McQueen, J., Scudder, C., Boyd, K. A., Briggs, A., Waterston, A., Medley, L., Wilson, C., Ellis, R., Essapen, S., Dhadda, A. S., Harrison, M., Falk, S., Raouf, S., Rees, C., Olesen, R. K., Propper, D., Bridgewater, J., Azzabi, A., Farrugia, D., Webb, A., Cunningham, D., Hickish, T., Weaver, A., Gollins, S., Wasan, H. S., Paul, J. (2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. LANCET ONCOLOGY, 19 (4). pp. 562-578. ISSN 1470-2045

Formica, V., Leary, A., Cunningham, D., Chua, Y. J. (2006) 5-Fluorouracil can cross brain-blood barrier and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 58 (2). pp. 276-278. ISSN 0344-5704

Smyth, E. C., Khan, K., Cunningham, D. (2016) AREG and EREG as Predictive Biomarkers for RAS Wild-Type Colorectal Cancer Treated With Panitumumab A Fresh Approach to an Old Puzzle. Jama Oncology, 2 (5). pp. 578-579. ISSN 2374-2445

Smyth, E. C., Cunningham, D. (2018) Adjuvant Chemotherapy Following Neoadjuvant Chemotherapy Plus Surgery for Patients With Gastroesophageal Cancer-Is There Room for Improvement? JAMA ONCOLOGY, 4 (1). pp. 38-39. ISSN 2374-2437

Van Cutsem, E., Joulain, F., Hoff, P. M., Mitchell, E., Ruff, P., Lakomy, R., Prausova, J., Moiseyenko, V. M., van Hazel, G., Cunningham, D., Arnold, D., Schmoll, H. J., ten Tije, A. J., McKendrick, J., Kroning, H., Humblet, Y., Gravalos, C., Le-Guennec, S., Andria, M., Dochy, E., Vishwanath, R. L., Macarulla, T., Tabernero, J. (2016) Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. TARGETED ONCOLOGY, 11 (3). pp. 383-400. ISSN 1776-2596

Markar, S. R., Wiggins, T., Antonowicz, S., Chin, S. T., Romano, A., Nikolic, K., Evans, B., Cunningham, D., Mughal, M., Lagergren, J., Hanna, G. B. (2018) Assessment of a Noninvasive Exhaled Breath Test for the Diagnosis of Oesophagogastric Cancer. JAMA ONCOLOGY, 4 (7). pp. 970-976. ISSN 2374-2437

Glynne-Jones, R., Sebag-Montefiore, D., Meadows, H. M., Cunningham, D., Begum, R., Adab, F., Benstead, K., Harte, R. J., Stewart, J., Beare, S., Hackshaw, A., Kadalayil, L., Grp, Act Ii Study (2017) Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. LANCET ONCOLOGY, 18 (3). pp. 347-356. ISSN 1470-2045

Hale, M. D., Nankivell, M., Hutchins, G. G., Stenning, S. P., Langley, R. E., Mueller, W., West, N. P., Wright, A. I., Treanor, D., Hewitt, L. C., Allum, W. H., Cunningham, D., Hayden, J. D., Grabsch, H. I. (2016) Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma - results from the UK MRC OE02 trial. Oncotarget, 7 (47). pp. 77565-77575. ISSN 1949-2553

Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illes, A., Picardi, M., Lech-Maranda, E., Oki, Y., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Chen, R., Ramchandren, R., Zinzani, P. L., Cunningham, D., Rosta, A., Josephson, N. C., Song, E., Sachs, J., Liu, R., Jolin, H. A., Huebner, D., Radford, J., Grp, E. CHELON-1Study (2018) Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 378 (4). pp. 331-344. ISSN 0028-4793

Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illes, A., Picardi, M., Lech-Maranda, E., Oki, Y., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Chen, R., Ramchandren, R., Zinzani, P. L., Cunningham, D., Rosta, A., Josephson, N. C., Song, E., Sachs, J., Liu, R., Jolin, H. A., Huebner, D., Radford, J., Grp, E. CHELON-1Study (2018) Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 378 (4). pp. 331-344. ISSN 0028-4793

Amorim, S., Stathis, A., Gleeson, M., Iyengar, S., Magarotto, V., Leleu, X., Morschhauser, F., Karlin, L., Broussais, F., Rezai, K., Herait, P., Kahatt, C., Lokiec, F., Salles, G., Facon, T., Palumbo, A., Cunningham, D., Zucca, E., Thieblemont, C. (2016) Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematology, 3 (4). E196-E204. ISSN 2352-3026

Dangoor, A., Joffe, J., Januszewski, A., Mansi, J., Cunningham, D., Selby, P., Assoc Canc Phys, U. K. (2016) CANCER DRUGS, SURVIVAL, AND ETHICS The Association of Cancer Physicians responds to "Cancer drugs, survival, and ethics". Bmj-British Medical Journal, 355. ISSN 1756-1833

Gleeson, M., Counsell, N., Cunningham, D., Chadwick, N., Lawrie, A., Hawkes, E. A., McMillan, A., Ardeshna, K. M., Jack, A., Smith, P., Mouncey, P., Pocock, C., Radford, J. A., Davies, J., Turner, D., Kruger, A., Johnson, P., Gambell, J., Linch, D. (2017) Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. ANNALS OF ONCOLOGY, 28 (10). pp. 2511-2516. ISSN 0923-7534

Backen, A. C., Lopes, A., Wasan, H., Palmer, D. H., Duggan, M., Cunningham, D., Anthoney, A., Corrie, P. G., Madhusudan, S., Maraveyas, A., Ross, P. J., Waters, J. S., Steward, W. P., Rees, C., McNamara, M. G., Beare, S., Bridgewater, J. A., Dive, C., Valle, J. W. (2018) Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. BRITISH JOURNAL OF CANCER, 119 (1). pp. 27-35. ISSN 0007-0920

Davidson, M., Smyth, E. C., Cunningham, D. (2016) Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma. Oncotargets and Therapy, 9. pp. 4539-4548. ISSN 1178-6930

Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., Darby, S., Meyer, T., Gillmore, R., Anthoney, A., Lind, P., Glimelius, B., Falk, S., Izbicki, J. R., Middleton, G. W., Cummins, S., Ross, P. J., Wasan, H., McDonald, A., Crosby, T., Ma, Y. T., Patel, K., Sherriff, D., Soomal, R., Borg, D., Sothi, S., Hammel, P., Hackert, T., Jackson, R., Buchler, M. W., European Study Grp Pancreat, Canc (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. LANCET, 389 (10073). pp. 1011-1024. ISSN 0140-6736

Sclafani, F., Kim, T. Y., Cunningham, D., Kim, T. W., Tabernero, J., Schmoll, H. J., Roh, J. K., Kim, S. Y., Park, Y. S., Guren, T. K., Hawkes, E., Clarke, S. J., Ferry, D., Frodin, J. E., Ayers, M., Nebozhyn, M., Peckitt, C., Loboda, A., Watkins, D. J. (2017) Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. INTERNATIONAL JOURNAL OF CANCER, 140 (2). pp. 431-439. ISSN 0020-7136

Shah, M. A., Bang, Y. J., Lordick, F., Alsina, M., Chen, M., Hack, S. P., Bruey, J. M., Smith, D., McCaffery, I., Shames, D. S., Phan, S., Cunningham, D. (2017) Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma The METGastric Randomized Clinical Trial. Jama Oncology, 3 (5). pp. 620-627. ISSN 2374-2445

Markar, S. R., Mackenzie, H., Jemal, S., Faiz, O., Cunningham, D., Hanna, G. B. (2018) Emergency Presentation of Esophagogastric Cancer Predictors and Long-term Prognosis. ANNALS OF SURGERY, 267 (4). pp. 711-715. ISSN 0003-4932

Smyth, E. C., Cunningham, D. (2016) Encouraging results for PD-1 inhibition in gastric cancer. LANCET ONCOLOGY, 17 (6). pp. 682-683. ISSN 1470-2045

Hewitt, L. C., Inam, I. Z., Saito, Y., Yoshikawa, T., Quaas, A., Hoelscher, A., Bollschweiler, E., Fazzi, G. E., Melotte, V., Langley, R. E., Nankivell, M., Cunningham, D., Allum, W., Hutchins, G. G., Grabsch, H. I. (2018) Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study. EUROPEAN JOURNAL OF CANCER, 94. pp. 104-114. ISSN 0959-8049

Fontana, E., Smyth, E. C., Cunningham, D. (2016) Esophagogastric Adenocarcinoma: Is More Chemotherapy Better? CURRENT TREATMENT OPTIONS IN ONCOLOGY, 17 (5). p. 15. ISSN 1527-2729

Del Chiaro, M., Besselink, M. G., Scholten, L., Bruno, M. J., Cahen, D. L., Gress, T. M., van Hooft, J. E., Lerch, M. M., Mayerle, J., Hackert, T., Satoi, S., Zerbi, A., Cunningham, D., De Angelis, C., Giovannini, M., de-Madaria, E., Hegyi, P., Rosendahl, J., Friess, H., Manfredi, R., Levy, P., Real, F. X., Sauvanet, A., Abu Hilal, M., Marchegiani, G., Esposito, I., Ghaneh, P., Engelbrecht, M. R. W., Fockens, P., van Huijgevoort, N. C. M., Wolfgang, C., Bassi, C., Gubergrits, N. B., Verbeke, C., Kloppel, G., Scarpa, A., Zamboni, G., Lennon, A. M., Sund, M., Kartalis, N., Grenacher, L., Falconi, M., Arnelo, U., Kopchak, K. V., Oppong, K., McKay, C., Hauge, T., Conlon, K., Adham, M., Ceyhan, G. O., Salvia, R., Dervenis, C., Allen, P., Paye, F., Bartsch, D. K., Lohr, M., Mutignani, M., Laukkarinen, J., Schulick, R., Valente, R., Seufferlein, T., Capurso, G., Siriwardena, A., Neoptolemos, J. P., Pukitis, A., Segersvard, R., Aghdassi, A., Andrianello, S., Bossuyt, P., Bulow, R., Cardenas-Jaen, K., Cortegoso, P., Fontana, M., Haeberle, L., Heckler, M., Litvin, A., Mann, K., Michalski, C., Michl, P., Nappo, G., Perri, G., Persson, S., Scheufele, F., Sclafani, F., Schmidt, M., Venezia, L., Volker, F., Vullierm, M. P., Wusten, L., European Study Grp Cystic, Tum (2018) European evidence-based guidelines on pancreatic cystic neoplasms. GUT, 67 (5). pp. 789-804. ISSN 0017-5749

Smyth, E. C., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., Arnold, D., Comm, Esmo Guidelines (2016) Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, 27. v38-v49. ISSN 0923-7534

Crosby, T., Hurt, C. N., Falk, S., Gollins, S., Staffurth, J., Ray, R., Bridgewater, J. A., Geh, J. I., Cunningham, D., Blazeby, J., Roy, R., Maughan, T., Griffiths, G., Mukherjee, S. (2017) Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy plus /- cetuximab in oesophageal cancer. BRITISH JOURNAL OF CANCER, 116 (6). pp. 709-716. ISSN 0007-0920

Davies, A. R., Myoteri, D., Zylstra, J., Baker, C. R., Wulaningsih, W., Van Hemelrijck, M., Maisey, N., Allum, W. H., Smyth, E., Gossage, J. A., Lagergren, J., Cunningham, D., Green, M., St Thomas Oesophago-Gastric Res, Gr, Grp, Progress Study (2018) Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma. BRITISH JOURNAL OF SURGERY, 105 (12). pp. 1639-1649. ISSN 0007-1323

Alderson, D., Nankivell, M., Langley, R., Cunningham, D. (2017) Neoadjuvant chemotherapy in oesophageal adenocarcinoma Reply. LANCET ONCOLOGY, 18 (11). E641-E641. ISSN 1470-2045

Alderson, D., Cunningham, D., Nankivell, M., Blazeby, J. M., Griffin, S. M., Crellin, A., Grabsch, H. I., Langer, R., Pritchard, S., Okines, A., Krysztopik, R., Coxon, F., Thompson, J., Falk, S., Robb, C., Stenning, S., Langley, R. E. (2017) Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. LANCET ONCOLOGY, 18 (9). pp. 1249-1260. ISSN 1470-2045

Smyth, E. C., Lagergren, J., Fitzgerald, R. C., Lordick, F., Shah, M. A., Lagergren, P., Cunningham, D. (2017) Oesophageal cancer. NATURE REVIEWS DISEASE PRIMERS, 3. ISSN 2056-676X

Lagergren, J., Smyth, E., Cunningham, D., Lagergren, P. (2017) Oesophageal cancer. LANCET, 390 (10110). pp. 2383-2396. ISSN 0140-6736

Kuhnl, A., Cunningham, D., Counsell, N., Hawkes, E. A., Qian, W., Smith, P., Chadwick, N., Lawrie, A., Mouncey, P., Jack, A., Pocock, C., Ardeshna, K. M., Radford, J., McMillan, A., Davies, J., Turner, D., Kruger, A., Johnson, P. W., Gambell, J., Rosenwald, A., Ott, G., Horn, H., Ziepert, M., Pfreundschuh, M., Linch, D. (2017) Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. ANNALS OF ONCOLOGY, 28 (7). pp. 1540-1546. ISSN 0923-7534

Ghaneh, P., Hanson, R., Titman, A., Lancaster, G., Plumpton, C., Lloyd-Williams, H., Yeo, S. T., Edwards, R. T., Johnson, C., Abu Hilal, M., Higginson, A. P., Armstrong, T., Smith, A., Scarsbrook, A., McKay, C., Carter, R., Sutcliffe, R. P., Bramhall, S., Kocher, H. M., Cunningham, D., Pereira, S. P., Davidson, B., Chang, D., Khan, S., Zealley, I., Sarker, D., Al Sarireh, B., Charnley, R., Lobo, D., Nicolso, M., Halloran, C., Raraty, M., Sutton, R., Vinjamuri, S., Evans, J., Campbell, F., Deeks, J., Sanghera, B., Wong, W. L., Neoptolemos, J. P. (2018) PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality (18)fluorine-2-fluoro-2-deoxy-D-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. HEALTH TECHNOLOGY ASSESSMENT, 22 (7). ISSN 1366-5278

Pugh, S. A., Bowers, M., Ball, A., Falk, S., Finch-Jones, M., Valle, J. W., O'Reilly, D. A., Siriwardena, A. K., Hornbuckle, J., Rees, M., Rees, C., Iveson, T., Hickish, T., Maishman, T., Stanton, L., Dixon, E., Corkhill, A., Radford, M., Garden, O. J., Cunningham, D., Maughan, T. S., Bridgewater, J. A., Primrose, J. N. (2016) Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. BRITISH JOURNAL OF CANCER, 115 (4). pp. 420-424. ISSN 0007-0920

Smyth, E. C., Allum, W. H., Rowley, S., Langley, R. E., Cunningham, D. (2017) Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma. LANCET ONCOLOGY, 18 (5). E244-E244. ISSN 1470-2045

Cunningham, D., Stenning, S. P., Smyth, E. C., Okines, A. F., Allum, W. H., Rowley, S., Stevenson, L., Grabsch, H. I., Alderson, D., Crosby, T., Griffin, S. M., Mansoor, W., Coxon, F. Y., Falk, S. J., Darby, S., Sumpter, K. A., Blazeby, J. M., Langley, R. E. (2017) Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. LANCET ONCOLOGY, 18 (3). pp. 357-370. ISSN 1470-2045

Aggelis, V., Cunningham, D., Lordick, F., Smyth, E. C. (2018) Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future. ANNALS OF ONCOLOGY, 29 (6). pp. 1377-1385. ISSN 0923-7534

Dreyling, M., Morschhauser, F., Bouabdallah, K., Bron, D., Cunningham, D., Assouline, S. E., Verhoef, G., Linton, K., Thieblemont, C., Vitolo, U., Hiemeyer, F., Giurescu, M., Garcia-Vargas, J., Gorbatchevsky, I., Liu, L., Koechert, K., Pena, C., Neves, M., Childs, B. H., Zinzani, P. L. (2017) Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. ANNALS OF ONCOLOGY, 28 (9). pp. 2169-2178. ISSN 0923-7534

Ceriani, L., Martelli, M., Gospodarowicz, M. K., Ricardi, U., Ferreri, A. J. M., Chiappella, A., Stelitano, C., Balzarotti, M., Cabrera, M. E., Cunningham, D., Guarini, A., Zinzani, P. L., Giovanella, L., Johnson, P. W. M., Zucca, E. (2017) Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 97 (1). pp. 42-49. ISSN 0360-3016

Shi, Q., Schmitz, N., Ou, F. S., Dixon, J. G., Cunningham, D., Pfreundschuh, M., Seymour, J. F., Jaeger, U., Habermann, T. M., Haioun, C., Tilly, H., Ghesquieres, H., Merli, F., Ziepert, M., Herbrecht, R., Flament, J., Fu, T., Coiffier, B., Flowers, C. R. (2018) Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). JOURNAL OF CLINICAL ONCOLOGY, 36 (25). pp. 2593-2602. ISSN 0732-183X

Maurer, M. J., Habermann, T. M., Shi, Q., Schmitz, N., Cunningham, D., Pfreundschuh, M., Seymour, J. F., Jaeger, U., Haioun, C., Tilly, H., Ghesquieres, H., Merli, F., Ziepert, M., Herbrecht, R., Flament, J., Fu, T., Flowers, C. R., Coiffier, B. (2018) Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. ANNALS OF ONCOLOGY, 29 (8). pp. 1822-1827. ISSN 0923-7534

Bridgewater, J., Lopes, A., Palmer, D., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Valle, J., Wasan, H., Investigators, A. B. C. (2016) Quality of life, long-term survivors and long-term outcome from the ABC-02 study. BRITISH JOURNAL OF CANCER, 114 (9). pp. 965-971. ISSN 0007-0920

Obulkasim, A., Ylstra, B., van Essen, H. F., Benner, C., Stenning, S., Langley, R., Allum, W., Cunningham, D., Inam, I., Hewitt, L. C., West, N. P., Meijer, G. A., van de Wiel, M. A., Grabsch, H. I. (2016) Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma. Oncotarget, 7 (28). pp. 44084-44095. ISSN 1949-2553

Khan, K., Cunningham, D., Aitken, K., Rao, S. (2017) Regarding "Survival Outcomes in Asymptomatic Patients with Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging" In Reply. ONCOLOGIST, 22 (11). pp. 1411-1412. ISSN 1083-7159

Catenacci, D. V. T., Tebbutt, N. C., Davidenko, I., Murad, A. M., Al-Batran, S. E., Ilson, D. H., Tjulandin, S., Gotovkin, E., Karaszewska, B., Bondarenko, I., Tejani, M. A., Udrea, A. A., Tehfe, M., De Vita, F., Turkington, C., Tang, R., Ang, A., Zhang, Y. L., Hoang, T., Sidhu, R., Cunningham, D. (2017) Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. LANCET ONCOLOGY, 18 (11). pp. 1467-1482. ISSN 1470-2045

Gleeson, M., Hawkes, E. A., Cunningham, D., Chadwick, N., Counsell, N., Lawrie, A., Jack, A., Smith, P., Mouncey, P., Pocock, C., Ardeshna, K. M., Radford, J., McMillan, A., Davies, J., Turner, D., Kruger, A., Johnson, P. W. M., Gambell, J., Linch, D. (2016) Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. BRITISH JOURNAL OF HAEMATOLOGY, 175 (4). pp. 668-672. ISSN 0007-1048

Cartwright, E., Cunningham, D. (2017) The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 18 (12). ISSN 1527-2729

McNamara, M. G., Bridgewater, J., Lopes, A., Wasan, H., Malka, D., Jensen, L. H., Okusaka, T., Knox, J. J., Wagner, D., Cunningham, D., Shannon, J., Goldstein, D., Moehler, M., Bekaii-Saab, T., Valle, J. W. (2017) Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. BMC CANCER, 17. ISSN 1471-2407

Middleton, G., Palmer, D. H., Greenhalf, W., Ghaneh, P., Jackson, R., Cox, T., Evans, A., Shaw, V. E., Wadsley, J., Valle, J. W., Propper, D., Wasan, H., Falk, S., Cunningham, D., Coxon, F., Ross, P., Madhusudan, S., Wadd, N., Corrie, P., Hickish, T., Costello, E., Campbell, F., Rawcliffe, C., Neoptolemos, J. P. (2017) Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. LANCET ONCOLOGY, 18 (4). pp. 486-499. ISSN 1470-2045

Cunningham, D., Starling, N. (2007) Adjuvant chemotherapy of colorectal cancer. LANCET, 370 (9604). pp. 1980-1981. ISSN 0140-6736

Neoptolemos, J. P., Stocken, D. D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M. J., Gallinger, S., Mariette, C., Wente, M. N., Izbicki, J. R., Friess, H., Lerch, M. M., Dervenis, C., Olah, A., Butturini, G., Doi, R., Lind, P. A., Smith, D., Valle, J. W., Palmer, D. H., Buckels, J. A., Thompson, J., McKay, C. J., Rawcliffe, C. L., Buechler, M. W., European Study Grp Pancreatic Canc, [Group Author] (2010) Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 304 (10). pp. 1073-1081. ISSN 0098-7484

Moorcraft, S. Y., Smyth, E. C., Cunningham, D. (2015) Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? Gastric Cancer, 18 (1). pp. 1-10. ISSN 1436-3291

Rao, S., Cunningham, D. (2003) Adjuvant therapy for colon cancer in the new millenium. SCANDINAVIAN JOURNAL OF SURGERY, 92 (1). pp. 57-64. ISSN 1457-4969

Neoptolemos, J. P., Cunningham, D., Friess, H., Bassi, C., Stocken, D. D., Tait, D. M., Dunn, J. A., Dervenis, C., Lacaine, F., Hickey, H., Raraty, M. G. T., Ghaneh, P., Buchler, M. W. (2003) Adjuvant therapy in pancreatic cancer: historical and current perspectives. ANNALS OF ONCOLOGY, 14 (5). pp. 675-692. ISSN 0923-7534

Chua, Y. J., Cunningham, D. (2005) Adjuvant treatment for resectable pancreatic cancer. JOURNAL OF CLINICAL ONCOLOGY, 23 (20). pp. 4532-4537. ISSN 0732-183X

Van Cutsem, E., Dicato, M., Wils, J., Cunningham, D., Diaz-Rubio, E., Glimelius, B., Haller, D., Johnston, P., Kerr, D., Koehne, C. H., Labianca, R., Minsky, B., Nordlinger, B., Roth, A., Rougier, P., Schmoll, H. J. (2002) Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). EUROPEAN JOURNAL OF CANCER, 38 (11). pp. 1429-1436. ISSN 0959-8049

Rao, S., Cunningham, D. (2002) Advanced pancreatic cancer - 5 years on. ANNALS OF ONCOLOGY, 13 (8). pp. 1165-1168. ISSN 0923-7534

Thirion, P., Piedbois, P., Buyse, M., O'Dwyer, P. J., Cunningham, D., Man, A., Greco, F. A., Colucci, G., Kohne, C. H., Di Constanzo, F., Piga, A., Palmeri, S., Dufour, P., Cassano, A., Pajkos, G., Pensel, R. A., Aykan, N. F., Marsh, J., Seymour, M. T., Meta-Analysis Group in Cancer, [Group Author] (2001) Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. BRITISH JOURNAL OF CANCER, 84 (5). pp. 611-620. ISSN 0007-0920

Hawkes, E., Cunningham, D. (2010) Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer? LANCET ONCOLOGY, 11 (11). pp. 1020-1021. ISSN 1470-2045

Barton, S., Hawkes, E. A., Wotherspoon, A., Cunningham, D. (2012) Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks? ONCOLOGIST, 17 (12). pp. 1562-1573. ISSN 1083-7159

Sclafani, F., Cunningham, D. (2014) Bevacizumab in elderly patients with metastatic colorectal cancer. Journal of Geriatric Oncology, 5 (1). pp. 78-88. ISSN 1879-4068

Cunningham, D., Lang, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D. B., Jonker, D., Osborne, S., Andre, N., Waterkamp, D., Saunders, M. P., Investigators, Avex Study (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. LANCET ONCOLOGY, 14 (11). pp. 1077-1085. ISSN 1470-2045

de Gramont, A., Van Cutsem, E., Schmoll, H. J., Tabernero, J., Clarke, S., Moore, M. J., Cunningham, D., Cartwright, T. H., Hecht, J. R., Rivera, F., Im, S. A., Bodoky, G., Salazar, R., Maindrault-Goebel, F., Shacham-Shmueli, E., Bajetta, E., Makrutzki, M., Shang, A. J., Andre, T., Hoff, P. M. (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. LANCET ONCOLOGY, 13 (12). pp. 1225-1233. ISSN 1470-2045

Okines, A. F. C., Langley, R. E., Thompson, L. C., Stenning, S. P., Stevenson, L., Falk, S., Seymour, M., Coxon, F., Middleton, G. W., Smith, D., Evans, L., Slater, S., Waters, J., Ford, D., Hall, M., Iveson, T. J., Petty, R. D., Plummer, C., Allum, W. H., Blazeby, J. M., Griffin, M., Cunningham, D. (2013) Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. ANNALS OF ONCOLOGY, 24 (3). pp. 702-709. ISSN 0923-7534

Maisey, N. R., Norman, A. R., Hill, A., Massey, A., Oates, J., Cunningham, D. (2005) CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. BRITISH JOURNAL OF CANCER, 93 (7). pp. 740-743. ISSN 0007-0920

Chong, G., Cunningham, D. (2005) Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial. CLINICAL ONCOLOGY, 17 (2). pp. 79-80. ISSN 0936-6555

Chong, G., Dickson, J. L. B., Cunningham, D., Norman, A. R., Rao, S., Hill, M. E., Price, T. J., Oates, J., Tebbutt, N. (2005) Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. BRITISH JOURNAL OF CANCER, 93 (5). pp. 510-514. ISSN 0007-0920

Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., Norman, A. R., Natl Canc Res Inst United Kingdom, [Group Author] (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. NEW ENGLAND JOURNAL OF MEDICINE, 358 (1). pp. 36-46. ISSN 0028-4793

Cunningham, D., Starling, N. (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer - Reply. NEW ENGLAND JOURNAL OF MEDICINE, 358 (18). p. 1965. ISSN 0028-4793

Cunningham, D., Okines, A. F. C., Ashley, S. (2010) Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 362 (9). pp. 858-859. ISSN 0028-4793

Meyer, T., Qian, W. D., Caplin, M. E., Armstrong, G., Lao-Sirieix, S. H., Hardy, R., Valle, J. W., Talbot, D. C., Cunningham, D., Reed, N., Shaw, A., Navalkissoor, S., Luong, T. V., Corrie, P. G. (2014) Capecitabine and streptozocin +/- cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. EUROPEAN JOURNAL OF CANCER, 50 (5). pp. 902-911. ISSN 0959-8049

Rothenberg, M. L., Cox, J. V., Butts, C., Navarro, M., Bang, Y. J., Goel, R., Gollins, S., Siu, L. L., Laguerre, S., Cunningham, D. (2008) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. ANNALS OF ONCOLOGY, 19 (10). pp. 1720-1726. ISSN 0923-7534

Tebbutt, N. C., Wilson, K., Gebski, V. J., Cummins, M. M., Zannino, D., van Hazel, G. A., Robinson, B., Broad, A., Ganju, V., Ackland, S. P., Forgeson, G., Cunningham, D., Saunders, M. P., Stockler, M. R., Chua, Y., Zalcberg, J. R., Simes, R. J., Price, T. J. (2010) Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. JOURNAL OF CLINICAL ONCOLOGY, 28 (19). pp. 3191-3198. ISSN 0732-183X

Khawaja, M. Z., Cafferkey, C., Rajani, R., Redwood, S., Cunningham, D. (2014) Cardiac complications and manifestations of chemotherapy for cancer. HEART, 100 (14). pp. 1133-1140. ISSN 1355-6037

Hawkes, E. A., Okines, A. F. C., Plummer, C., Cunningham, D. (2011) Cardiotoxicity in Patients Treated With Bevacizumab Is Potentially Reversible. JOURNAL OF CLINICAL ONCOLOGY, 29 (18). E560-E562. ISSN 0732-183X

Neofytou, K., Giakoustidis, A., Smyth, E. C., Cunningham, D., Mudan, S. (2015) A Case of Metastatic Pancreatic Adenocarcinoma With Prolonged Survival After Combination of Neoadjuvant FOLFIRINOX Therapy and Synchronous Distal Pancreatectomy and Hepatectomy. JOURNAL OF SURGICAL ONCOLOGY, 111 (6). pp. 768-770. ISSN 0022-4790

Gleeson, M., Hawkes, E. A., Cunningham, D., Jack, A., Linch, D. (2015) Caution in the Use of Immunohistochemistry for Determination of Cell of Origin in Diffuse Large B-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 33 (28). pp. 3215-3216. ISSN 0732-183X

Mendes, L. S. T., Attygalle, A. D., Cunningham, D., Benson, M., Andreyev, J., Gonzales-de-Castro, D., Wotherspoon, A. (2014) CD4-positive small T-cell lymphoma of the intestine presenting with severe bile-acid malabsorption: a supportive symptom control approach. BRITISH JOURNAL OF HAEMATOLOGY, 167 (2). pp. 265-269. ISSN 0007-1048

Valle, J. W., Wasan, H., Lopes, A., Backen, A. C., Palmer, D. H., Morris, K., Duggan, M., Cunningham, D., Anthoney, D. A., Corrie, P., Madhusudan, S., Maraveyas, A., Ross, P. J., Waters, J. S., Steward, W. P., Rees, C., Beare, S., Dive, C., Bridgewater, J. A. (2015) Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. LANCET ONCOLOGY, 16 (8). pp. 967-978. ISSN 1470-2045

Schmoll, H. J., Cunningham, D., Sobrero, A., Karapetis, C. S., Rougier, P., Koski, S. L., Kocakova, I., Bondarenko, I., Bodoky, G., Mainwaring, P., Salazar, R., Barker, P., Mookerjee, B., Robertson, J., Van Cutsem, E. (2012) Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III). JOURNAL OF CLINICAL ONCOLOGY, 30 (29). pp. 3588-3595. ISSN 0732-183X

Cunningham, D., Wong, R. P. W., D'Haens, G., Douillard, J. Y., Robertson, J., Stone, A. M., Van Cutsem, E., Grp, Horizon I. Study (2013) Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. BRITISH JOURNAL OF CANCER, 108 (3). pp. 493-502. ISSN 0007-0920

Ng, M., Cunningham, D. (2004) Cetuximab (Erbitux) - an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 58 (10). pp. 970-976. ISSN 1368-5031

Primrose, John N., Cunningham, David, Garden, O. James, Maughan, Tim S., Pugh, Sian A., Stanton, Louise, Falk, Stephen J., Rees, Myrddin, Finch-Jones, Meg, Valle, Juan W., O'Reilly, Derek, Hornbuckle, Joanne, Hickish, Tamas, Bridgewater, John A. (2015) Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases. JOURNAL OF CLINICAL ONCOLOGY, 33 (21). 2405-U108. ISSN 0732-183X

Sclafani, F., Cunningham, D. (2014) Cetuximab or bevacizumab in metastatic colorectal cancer? LANCET ONCOLOGY, 15 (10). pp. 1040-1041. ISSN 1470-2045

Van Cutsem, E., Kohne, C. H., Lang, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., Schlichting, M., Zubel, A., Celik, I., Rougier, P., Ciardiello, F. (2011) Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. JOURNAL OF CLINICAL ONCOLOGY, 29 (15). pp. 2011-2019. ISSN 0732-183X

Starling, N., Cunningham, D. (2006) Cetuximab-associated infusion reactions: Pathology and management - The Patel/Goldberg article reviewed. ONCOLOGY-NEW YORK, 20 (11). 1394-+. ISSN 0890-9091

Waters, J., Cunningham, D. (2001) The changing face of chemotherapy in colorectal cancer. BRITISH JOURNAL OF CANCER, 84 (1). pp. 1-7. ISSN 0007-0920

Crosby, T., Hurt, C. N., Falk, S., Gollins, S., Mukherjee, S., Staffurth, J., Ray, R., Bashir, N., Bridgewater, J. A., Geh, J. I., Cunningham, D., Blazeby, J., Roy, R., Maughan, T., Griffiths, G. (2013) Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. LANCET ONCOLOGY, 14 (7). pp. 627-637. ISSN 1470-2045

Chua, Y. J., Cunningham, D. (2006) Chemotherapy for advanced pancreatic cancer. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY, 20 (2). pp. 327-348. ISSN 1521-6918

Maisey, N., Norman, A., Prior, Y., Cunningham, D. (2004) Chemotherapy for primary gastric lymphoma: Does in-patient observation prevent complications?. CLINICAL ONCOLOGY, 16 (1). pp. 48-52. ISSN 0936-6555

Waddell, T. S., Cunningham, D. (2011) CHEMOTHERAPY Perioperative therapy improves gastroesophageal cancer survival. NATURE REVIEWS CLINICAL ONCOLOGY, 8 (8). pp. 450-452. ISSN 1759-4774

Cananzi, F. C. M., Jayanth, A., Lorenzi, B., Belgaumkar, A., Mochlinski, K., Sharma, A., Mudan, S., Cunningham, D. (2013) "Chronic" metastatic pancreatic acinar cell carcinoma. PANCREATOLOGY, 13 (5). pp. 549-552. ISSN 1424-3903

Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., Roughton, M., Bridgewater, J., ABC-02 Trial Investigators, [Group Author] (2010) Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 362 (14). pp. 1273-1281. ISSN 0028-4793

Cunningham, D., Falk, S., Jackson, D. (2002) Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. BRITISH JOURNAL OF CANCER, 86 (11). pp. 1677-1683. ISSN 0007-0920

Kohne, C. H., Cunningham, D., Di Costanzo, F., Glimelius, B., Blijham, G., Aranda, E., Scheithauer, W., Rougier, P., Palmer, M., Wils, J., Baron, B., Pignatti, F., Schoffski, P., Micheel, S., Hecker, H. (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. ANNALS OF ONCOLOGY, 13 (2). pp. 308-317. ISSN 0923-7534

Loveman, E., Jones, J., Clegg, A. J., Picot, J., Colquitt, J. L., Mendes, D., Breen, D. J., Moore, E., George, S., Poston, G., Cunningham, D., Ruers, T., Primrose, J. (2014) The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 18 (7). 1-+. ISSN 1366-5278

Massacesi, C., Norman, A., Price, T., Hill, M., Ross, P. J., Cunningham, D. (2001) A clinical nomogram for predicting long-term survival in advanced colorectal cancer. EUROPEAN JOURNAL OF CANCER, 36 (16). pp. 2044-2052. ISSN 0959-8049

Cunningham, D., Atkin, W., Lenz, H., Lynch, H. T., Minsky, B., Nordlinger, B., Starling, N. (2010) Colorectal cancer. LANCET, 375 (9719). pp. 1030-1047. ISSN 0140-6736

Cunningham, D., Minsky, B., Lenz, H. J., Nordlinger, B., Starling, N. (2010) Colorectal cancer Reply. LANCET, 376 (9738). pp. 331-332. ISSN 0140-6736

Su, Z., Gay, L. J., Strange, A., Palles, C., Band, G., Whiteman, D. C., Lescai, F., Langford, C., Nanji, M., Edkins, S., van der Winkel, A., Levine, D., Sasieni, P., Bellenguez, C., Howarth, K., Freeman, C., Trudgill, N., Tucker, A. T., Pirinen, M., Peppelenbosch, M. P., van der Laan, L. J. W., Kuipers, E. J., Drenth, J. P. H., Peters, W. H., Reynolds, J. V., Kelleher, D. P., McManus, R., Grabsch, H., Prenen, H., Bisschops, R., Krishnadath, K., Siersema, P. D., van Baal, Jwpm, Middleton, M., Petty, R., Gillies, R., Burch, N., Bhandari, P., Paterson, S., Edwards, C., Penman, I., Vaidya, K., Ang, Y., Murray, I., Patel, P., Ye, W. M., Mullins, P., Wu, A. H., Bird, N. C., Dallal, H., Shaheen, N. J., Murray, L. J., Koss, K., Bernstein, L., Romero, Y., Hardie, L. J., Zhang, R., Winter, H., Corley, D. A., Panter, S., Risch, H. A., Reid, B. J., Sargeant, I., Gammon, M. D., Smart, H., Dhar, A., McMurtry, H., Ali, H., Liu, G., Casson, A. G., Chow, W. H., Rutter, M., Tawil, A., Morris, D., Nwokolo, C., Isaacs, P., Rodgers, C., Ragunath, K., MacDonald, C., Haigh, C., Monk, D., Davies, G., Wajed, S., Johnston, D., Gibbons, M., Cullen, S., Church, N., Langley, R., Griffin, M., Alderson, D., Deloukas, P., Hunt, S. E., Gray, E., Dronov, S., Potter, S. C., Tashakkori-Ghanbaria, A., Anderson, M., Brooks, C., Blackwell, J. M., Bramon, E., et al. (2012) Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. NATURE GENETICS, 44 (10). 1131-+. ISSN 1061-4036

Price, T. J., Bruhn, M. A., Lee, C. K., Hardingham, J. E., Townsend, A. R., Mann, K. P., Simes, J., Weickhardt, A., Wrin, J. W., Wilson, K., Gebski, V., Van Hazel, G., Robinson, B., Cunningham, D., Tebbutt, N. C. (2015) Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. BRITISH JOURNAL OF CANCER, 112 (6). pp. 963-970. ISSN 0007-0920

Price, T. J., Bruhn, M. A., Lee, C. K., Hardingham, J. E., Townsend, A. R., Mann, K. P., Simes, J., Weickhardt, A., Wrin, J. W., Wilson, K., Gebski, V., Van Hazel, G., Robinson, B., Cunningham, D., Tebbutt, N. C. (2015) Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. BRITISH JOURNAL OF CANCER, 112 (6). pp. 963-970. ISSN 0007-0920

Bar, J., Spencer, S., Morgan, S., Brooks, L., Cunningham, D., Robertson, J., Jurgensmeier, J. M., Goss, G. D. (2014) Correlation of Lactate Dehydrogenase Isoenzyme Profile With Outcome in Patients With Advanced Colorectal Cancer Treated With Chemotherapy and Bevacizumab or Cediranib: Retrospective Analysis of the HORIZON I Study. CLINICAL COLORECTAL CANCER, 13 (1). pp. 46-53. ISSN 1533-0028

Starling, N., Tilden, D., White, J., Cunningham, D. (2007) Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. BRITISH JOURNAL OF CANCER, 96 (2). pp. 206-212. ISSN 0007-0920

Price, T. J., Tebbutt, N. C., Karapetis, C. S., Segelov, E., Pavlakis, N., Cunningham, D., Sobrero, A. F., Haller, D. G., Shapiro, J. D. (2010) Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. CLINICAL COLORECTAL CANCER, 9 (1). pp. 8-14. ISSN 1533-0028

Price, T. J., Segelov, E., Burge, M., Haller, D. G., Ackland, S. P., Tebbutt, N. C., Karapetis, C. S., Pavlakis, N., Sobrero, A. F., Cunningham, D., Shapiro, J. D. (2013) Current opinion on optimal treatment for colorectal cancer. EXPERT REVIEW OF ANTICANCER THERAPY, 13 (5). pp. 597-611. ISSN 1473-7140

Okines, A., Cunningham, D. (2009) Current perspective: Bevacizumab in colorectal cancer - A time for reappraisal? EUROPEAN JOURNAL OF CANCER, 45 (14). pp. 2452-2461. ISSN 0959-8049

Arkenau, H. T., Chua, Y. J., Cunningham, D. (2007) Current treatment strategies in elderly patients with metastatic colorectal cancer. CLINICAL COLORECTAL CANCER, 6 (7). pp. 508-515. ISSN 1533-0028

Fields, P. A., Townsend, W., Webb, A., Counsell, N., Pocock, C., Smith, P., Jack, A., El-Mehidi, N., Johnson, P. W., Radford, J., Linch, D. C., Cunnningham, D. (2014) De Novo Treatment of Diffuse Large B-Cell Lymphoma With Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in Patients With Cardiac Comorbidity: A United Kingdom National Cancer Research Institute Trial. JOURNAL OF CLINICAL ONCOLOGY, 32 (4). 282-+. ISSN 0732-183X

Chua, Y. J., Sargent, D., Cunningham, D. (2005) Definition of disease-free survival: this is my truth-show me yours. ANNALS OF ONCOLOGY, 16 (11). pp. 1719-1721. ISSN 0923-7534

Hawkes, E. A., Wotherspoon, A., Cunningham, D. (2012) Diagnosis and management of rare gastrointestinal lymphomas. LEUKEMIA & LYMPHOMA, 53 (12). pp. 2341-2350. ISSN 1042-8194

Van Cutsem, E., Dicat, M., Haustermans, K., Arber, N., Bosset, J. F., Cunningham, D., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Goldberg, R., Glynne-Jones, R., Haller, D., Kang, Y. K., Kerr, D., Labianca, R., Minsky, B. D., Moore, M., Nordlinger, B., Rougier, P., Scheithauer, W., Schmoll, H. J., Sobrero, A., Tabernero, J., Tempero, M., Van de Velde, C., Zalcberg, J. (2008) The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. ANNALS OF ONCOLOGY, 19 (Supple). vi1-vi8. ISSN 0923-7534

Payne, S., Burke, D., Mansi, J., Jones, A., Norton, A., Joffe, J., Cunningham, D., McVie, G., Agarwal, R. (2013) Discordance between cancer prevalence and training: a need for an increase in oncology education. CLINICAL MEDICINE, 13 (1). pp. 50-56. ISSN 1470-2118

Roy, A., Cunningham, D., Hawkins, R., Sorbye, H., Adenis, A., Barcelo, J. R., Lopez-Vivanco, G., Adler, G., Canon, J. L., Lofts, F., Castanon, C., Fonseca, E., Rixe, O., Aparicio, J., Cassinello, J., Nicolson, M., Mousseau, M., Schalhorn, A., D'Hondt, L., Kerger, J., Hossfeld, D. K., Giron, C. G., Rodriguez, R., Schoffski, P., Misset, J. L. (2012) Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. BRITISH JOURNAL OF CANCER, 107 (3). pp. 435-441. ISSN 0007-0920

Ratnayake, G., Cunningham, D. (2008) Does combining docetaxel with cisplatin and fluorouracil improve clinical benefit in advanced gastroesophageal cancer? NATURE CLINICAL PRACTICE ONCOLOGY, 5 (3). pp. 132-133. ISSN 1743-4254

Starling, N., Cunningham, D. (2007) Does shorter duration of chemotherapy worsen survival for elderly patients with colon cancer? NATURE CLINICAL PRACTICE ONCOLOGY, 4 (1). pp. 12-13. ISSN 1743-4254

Cunningham, D., Chua, Y. J. (2007) East meets west in the treatment of gastric cancer. NEW ENGLAND JOURNAL OF MEDICINE, 357 (18). pp. 1863-1865. ISSN 0028-4793

Coward, J., Maisey, N., Cunningham, D. (2005) The effects of capecitabine in Raynaud's disease: a case report. ANNALS OF ONCOLOGY, 16 (5). pp. 835-836. ISSN 0923-7534

Annels, N. E., Shaw, V. E., Gabitass, R. F., Billingham, L., Corrie, P., Eatock, M., Valle, J., Smith, D., Wadsley, J., Cunningham, D., Pandha, H., Neoptolemos, J. P., Middleton, G. (2014) The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. CANCER IMMUNOLOGY IMMUNOTHERAPY, 63 (2). pp. 175-183. ISSN 0340-7004

Trumper, M., Ross, P. J., Cunningham, D., Norman, A. R., Hawkins, R., Seymour, M., Harper, P., Iveson, T., Nicolson, M., Hickish, T. (2006) Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. EUROPEAN JOURNAL OF CANCER, 42 (7). pp. 827-834. ISSN 0959-8049

Folprecht, G., Cunningham, D., Ross, P., Glimelius, B., Di Costanzo, F., Wils, J., Scheithauer, W., Rougier, P., Aranda, E., Hecker, H., Kohne, C. H. (2004) Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. ANNALS OF ONCOLOGY, 15 (9). pp. 1330-1338. ISSN 0923-7534

Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J. P., Gilberg, F., Cunningham, D. (2011) Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. ANNALS OF ONCOLOGY, 22 (12). pp. 2604-2609. ISSN 0923-7534

Cunningham, D., Zalcberg, J., Maroun, J., James, R., Clarke, S., Maughan, T. S., Vincent, M., Schulz, J., Baron, M. G., Facchini, T. (2002) Efficacy, tolerability and management of raltitrexed (Tomudex TM) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trials. EUROPEAN JOURNAL OF CANCER, 38 (4). pp. 478-486. ISSN 0959-8049

Neofytou, K., Smyth, E. C., Giakoustidis, A., Khan, A. Z., Cunningham, D., Mudan, S. (2014) Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. MEDICAL ONCOLOGY, 31 (10). p. 9. ISSN 1357-0560

Smyth, E. C., Sclafani, F., Cunningham, D. (2014) Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Oncotargets and Therapy, 7. pp. 1001-1014. ISSN 1178-6930

Chua, Y. J., Cunningham, D. (2006) Emerging therapies for rectal cancer. COLORECTAL DISEASE, 8 (Supple). pp. 18-20. ISSN 1462-8910

Bianchini, D., Jayanth, A., Chua, Y. J., Cunningham, D. (2008) Epidermal growth factor receptor inhibitor-related skin toxicity: Mechanisms, treatment, and its potential role as a predictive marker. CLINICAL COLORECTAL CANCER, 7 (1). pp. 33-43. ISSN 1533-0028

Smyth, Elizabeth C., Cunningham, David (2015) Epirubicin, Cisplatin, and Capecitabine Versus Fluorouracil, Leucovorin, and Irinotecan for Esophagogastric Cancer: The Original and the Rest. JOURNAL OF CLINICAL ONCOLOGY, 33 (21). 2409-U116. ISSN 0732-183X

Ross, P. J., Cunningham, D. (2002) Epirubicin, cisplatin, and protracted venous-infusion fluorouracil in advanced esophagogastric cancer - Reply. JOURNAL OF CLINICAL ONCOLOGY, 20 (19). pp. 4124-4126. ISSN 0732-183X

Cunningham, D., Jost, L. M., Purkalne, G., Oliveira, J., ESMO Guidelines Working Grp, [Group Author] (2005) ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer. ANNALS OF ONCOLOGY, 16 (Supple). pp. 22-23. ISSN 0923-7534

Waddell, T., Cunningham, D. (2013) Evaluation of regorafenib in colorectal cancer and GIST. LANCET, 381 (9863). pp. 273-275. ISSN 0140-6736

Lowry, L., Smith, P., Cunningham, D., Linch, D. C. (2013) Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy. Journal of Geriatric Oncology, 4 (2). pp. 134-140. ISSN 1879-4068

Baldwin, C., McGough, C., Norman, A. R., Frost, G. S., Cunningham, D. C., Andreyev, H. J. N. (2006) Failure of dietetic referral in patients with gastrointestinal cancer and weight loss. EUROPEAN JOURNAL OF CANCER, 42 (15). pp. 2504-2509. ISSN 0959-8049

Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., Rivera, F., Kocakova, I., Ruff, P., Blasinska-Morawiec, M., Smakal, M., Canon, J. L., Rother, M., Oliner, K. S., Tian, Y., Xu, F., Sidhu, R. (2014) Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. ANNALS OF ONCOLOGY, 25 (7). pp. 1346-1355. ISSN 0923-7534

Hewish, M., Cunningham, D. (2011) First-line treatment of advanced colorectal cancer. LANCET, 377 (9783). pp. 2060-2062. ISSN 0140-6736

Ng, M., Cunningham, D., Norman, A. R. (2005) The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). EUROPEAN JOURNAL OF CANCER, 41 (11). pp. 1542-1546. ISSN 0959-8049

Smyth, E. C., Cunningham, D. (2013) GASTRIC CANCER IN 2012 Defining treatment standards and novel insights into disease biology. NATURE REVIEWS CLINICAL ONCOLOGY, 10 (2). pp. 73-74. ISSN 1759-4774

Ross P, Cunningham D. (2002) Gastric cancer. In: Oxford Handbook of Oncology. Oxford University Press., Oxford, UK, pp. 349-374. ISBN 978-019263035-3

Okines, A., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., ESMO Guidelines Working Grp, [Group Author] (2010) Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, 21 (Suppl.). v50-v54. ISSN 0923-7534

Cunningham, D., Oliveira, J., ESMO Guidelines Working Grp, [Group Author] (2008) Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, 19 (Supple). pp. 23-24. ISSN 0923-7534

Jackson, C., Cunningham, D., Oliveira, J., ESMO Guidelines Working Group, [Group Author] (2009) Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, 20 (Supple). pp. 34-36. ISSN 0923-7534

Waddell, T., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., Arnold, D. (2013) Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, 24. pp. 57-63. ISSN 0923-7534

Waddell, T., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., Arnold, D. (2014) Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. RADIOTHERAPY AND ONCOLOGY, 110 (1). pp. 189-194. ISSN 0167-8140

Waddell, T., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., Arnold, D. (2014) Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ejso, 40 (5). pp. 584-591. ISSN 0748-7983

Sumpter K, Cunningham D. (2003) Gastrointestinal cancer. In: Cancer in Primary Care. Martin Dunitz, London, UK, pp. 107-126. ISBN 978-190186526-4

Chong, G., Cunningham, D. (2005) Gastrointestinal cancer: recent developments in medical oncology. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 31 (5). pp. 453-460. ISSN 0748-7983

Smyth, E., Cunningham, D. (2012) Gastrointestinal oncology - what you need to know. CLINICAL MEDICINE, 12 (6). pp. 575-579. ISSN 1470-2118

Middleton, G., Silcocks, P., Cox, T., Valle, J., Wadsley, J., Propper, D., Coxon, F., Ross, P., Madhusudan, S., Roques, T., Cunningham, D., Falk, S., Wadd, N., Harrison, M., Corrie, P., Iveson, T., Robinson, A., McAdam, K., Eatock, M., Evans, J., Archer, C., Hickish, T., Garcia-Alonso, A., Nicolson, M., Steward, W., Anthoney, A., Greenhalf, W., Shaw, V., Costello, E., Naisbitt, D., Rawcliffe, C., Nanson, G., Neoptolemos, J. (2014) Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. LANCET ONCOLOGY, 15 (8). pp. 829-840. ISSN 1470-2045

Sultana, A., Ghaneh, P., Cunningham, D., Starling, N., Neoptolemos, J. P., Smith, C. T. (2008) Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC CANCER, 8. ISSN 1471-2407

Waddell, T., Cunningham, D. (2013) Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours. BRITISH JOURNAL OF SURGERY, 100 (1). pp. 5-14. ISSN 0007-1323

Chong, G., Cunningham, D. (2005) Improving long-term outcomes for patients with liver metastases from colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 23 (36). pp. 9063-9066. ISSN 0732-183X

Hewish, M., Chau, I., Cunningham, D. (2009) Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 4 (1). pp. 54-72. ISSN 1574-8928

Roth, A. D., Delorenzi, M., Tejpar, S., Yan, P., Klingbiel, D., Fiocca, R., d'Ario, G., Cisar, L., Labianca, R., Cunningham, D., Nordlinger, B., Bosman, F., Van Cutsem, E. (2012) Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 104 (21). pp. 1635-1646. ISSN 0027-8874

Cunningham, D., James, R. D. (2001) Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. EUROPEAN JOURNAL OF CANCER, 37 (7). pp. 826-834. ISSN 0959-8049

Tebbutt NC, Cunningham D. (2001) Integrating the use of molecular markers into the clinical management of patients with colorectal cancer. In: Progress in Colorectal Cancer 5: No 2. Mediscript Ltd., 2-Mar.

Jain, V. K., Hawkes, E. A., Cunningham, D. (2011) Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer. CLINICAL COLORECTAL CANCER, 10 (4). pp. 245-257. ISSN 1533-0028

Takaori, K., Bassi, C., Biankin, A., Brunner, T. B., Cataldo, I., Campbell, F., Cunningham, D., Falconi, M., Frampton, A. E., Furuse, J., Giovannini, M., Jackson, R., Nakamura, A., Nealon, W., Neoptolemos, J. P., Real, F. X., Scarpa, A., Sclafani, F., Windsor, J. A., Yamaguchi, K., Wolfgang, C., Johnson, C. D., Grp, Iap Epc Study (2016) International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. PANCREATOLOGY, 16 (1). pp. 14-27. ISSN 1424-3903

Tebbutt, N. C., Norman, A. R., Cunningham, D., Hill, M. E., Tait, D., Oates, J., Livingston, S., Andreyev, J. (2003) Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. GUT, 52 (4). pp. 568-573. ISSN 0017-5749

Cunningham, D. (2006) Is oxaliplatin the optimal platinum agent in gastric cancer? EJC SUPPLEMENTS, 4 (10). pp. 10-13. ISSN 1359-6349

Verslype, C., Van Cutsem, E., Dicato, M., Arber, N., Berlin, J. D., Cunningham, D., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Gruenberger, T., Haller, D., Haustermans, K., Hoff, P., Kerr, D., Labianca, R., Moore, M., Nordlinger, B., Ohtsu, A., Rougier, P., Scheithauer, W., Schmoll, H. -., Sobrero, A., Tabernero, J., van de Velde, C. (2009) The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. ANNALS OF ONCOLOGY, 20 (Suppl.). pp. 1-6. ISSN 0923-7534

Sclafani, F., Iyer, R., Cunningham, D., Starling, N. (2015) Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 95 (3). pp. 318-336. ISSN 1040-8428

Gordon, M. S., Cunningham, D. (2005) Managing patients treated with bevacizumab combination therapy. ONCOLOGY, 69 (Supple). pp. 25-33. ISSN 0030-2414

Andreyev, J., Cunningham, D. (2001) Markers, markers everywhere.. Prognosis in colorectal cancer - Time for a new approach. JOURNAL OF CLINICAL ONCOLOGY, 19 (2). pp. 286-288. ISSN 0732-183X

Rao, S., Starling, N., Cunningham, D., Sumpter, K., Gilligan, D., Ruhstaller, T., Valladares-Ayerbes, M., Wilke, H., Archer, C., Kurek, R., Beadman, C., Oates, J. (2010) Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. ANNALS OF ONCOLOGY, 21 (11). pp. 2213-2219. ISSN 0923-7534

Sultana, A., Smith, C. T., Cunningham, D., Starling, N., Neoptolemos, J. P., Ghaneh, P. (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. JOURNAL OF CLINICAL ONCOLOGY, 25 (18). pp. 2607-2615. ISSN 0732-183X

Sultana, A., Smith, C. T., Cunningham, D., Starling, N., Neoptolemos, J. P., Ghaneh, P. (2008) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. BRITISH JOURNAL OF CANCER, 99 (1). pp. 6-13. ISSN 0007-0920

Okines, A. F. C., Norman, A. R., McCloud, P., Kang, Y. K., Cunningham, D. (2009) Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. ANNALS OF ONCOLOGY, 20 (9). pp. 1529-1534. ISSN 0923-7534

Sumpter KA, Cunningham D. (2001) Metastatic rectal cancer. In: Modern Management of Cancer of the Rectum. Springer Verlag, Berlin, Germany, pp. 157-174. ISBN 978-185233287-7

Kelleher, M., Tebbutt, N. C., Cunningham, D., Andreyev, J., Allen, M., Hill, M., Norman, A. (2003) Mitomycin C, carboplatin and protracted venous infusion 5- fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies. CLINICAL ONCOLOGY, 15 (3). pp. 92-97. ISSN 0936-6555

James, R. D., Glynne-Jones, R., Meadows, H. M., Cunningham, D., Myint, A. S., Saunders, M. P., Maughan, T., McDonald, A., Essapen, S., Leslie, M., Falk, S., Wilson, C., Gollins, S., Begum, R., Ledermann, J., Kadalayil, L., Sebag-Montefiore, D. (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2x2 factorial trial. LANCET ONCOLOGY, 14 (6). pp. 516-524. ISSN 1470-2045

Starling, N., Cunningham, D. (2004) Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions. CURRENT OPINION IN ONCOLOGY, 16 (4). pp. 385-390. ISSN 1040-8746

Negri, F. V., Wotherspoon, A., Cunningham, D., Norman, A. R., Chong, G., Ross, P. J. (2005) Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. ANNALS OF ONCOLOGY, 16 (8). pp. 1305-1310. ISSN 0923-7534

Waters, J. S., Tait, D., Cunningham, D., Padhani, A. R., Hill, M. E., Falk, S., Lofts, F., Norman, A., Oates, J., Hill, A. (2002) A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus. ANNALS OF ONCOLOGY, 13 (11). pp. 1763-1770. ISSN 0923-7534

Tebbutt, N. C., Norman, A., Cunningham, D., Iveson, T., Seymour, M., Hickish, T., Harper, P., Maisey, N., Mochlinski, K., Prior, I., Hill, M. (2002) A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. ANNALS OF ONCOLOGY, 13 (10). pp. 1568-1575. ISSN 0923-7534

Okines, A. F. C., Cunningham, D. (2010) Multimodality treatment for localized gastro-oesophageal cancer. ANNALS OF ONCOLOGY, 21 (Suppl.). pp. 286-293. ISSN 0923-7534

Chau, I., Norman, A. R., Cunningham, D., Waters, J. S., Oates, J., Ross, P. J. (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. JOURNAL OF CLINICAL ONCOLOGY, 22 (12). pp. 2395-2403. ISSN 0732-183X

Wang-Gillam, A., Li, C. P., Bodoky, G., Dean, A., Shan, Y. S., Jameson, G., Macarulla, T., Lee, K. H., Cunningham, D., Blanc, J. F., Hubner, R. A., Chiu, C. F., Schwartsmann, G., Siveke, J. T., Braiteh, F., Moyo, V., Belanger, B., Dhindsa, N., Bayever, E., Von Hoff, D. D., Chen, L. T., Grp, Napoli- Study (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. LANCET, 387 (10018). pp. 545-557. ISSN 0140-6736

Van Cutsem, E., Dicato, M., Arber, N., Benson, A., Cunningham, D., Diaz-Rubio, E., Glimelius, B., Goldberg, R., Haller, D., Haustermans, K., Koo-Kang, Y., Labianca, R., Lang, I., Minsky, B., Nordlinger, B., Roth, A., Rougier, P., Schmoll, H. J., Sobrero, A., Tabernero, J., Szawlowski, A., de Velde, C. V. (2006) The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005. ANNALS OF ONCOLOGY, 17 (Supple). pp. 13-18. ISSN 0923-7534

Sclafani, F., Cunningham, D. (2014) Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. FUTURE ONCOLOGY, 10 (14). pp. 2243-2257. ISSN 1479-6694

Chua, Y. J., Cunningham, D. (2006) Neoadjuvant treatment of unresectable liver metastases from colorectal cancer. CLINICAL COLORECTAL CANCER, 5 (6). pp. 405-412. ISSN 1533-0028

Cunningham, D., Coleman, R. (2001) New options for outpatient chemotherapy - the role of oral fluoropyrimidines. CANCER TREATMENT REVIEWS, 27 (4). pp. 211-220. ISSN 0305-7372

Chong, G., Cunningham, D. (2004) Oesophageal cancer: preoperative chemotherapy. ANNALS OF ONCOLOGY, 15 (Supple). iv87-iv91. ISSN 0923-7534

Valle, J. W., Palmer, D., Jackson, R., Cox, T., Neoptolemos, J. P., Ghaneh, P., Rawcliffe, C. L., Bassi, C., Stocken, D. D., Cunningham, D., O'Reilly, D., Goldstein, D., Robinson, B. A., Karapetis, C., Scarfe, A., Lacaine, F., Sand, J., Izbicki, J. R., Mayerle, J., Dervenis, C., Olah, A., Butturini, G., Lind, P. A., Middleton, M. R., Anthoney, A., Sumpter, K., Carter, R., Bucher, M. W. (2014) Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study. JOURNAL OF CLINICAL ONCOLOGY, 32 (6). 504-+. ISSN 0732-183X

Smyth, E. C., Waddell, T. S., Cunningham, D. (2014) Optimal Management of Esophageal Adenocarcinoma: Should We Be CROSS? JOURNAL OF CLINICAL ONCOLOGY, 32 (27). p. 3080. ISSN 0732-183X

Bystricky, B., Okines, A. F. C., Cunningham, D. (2011) Optimal Therapeutic Strategies for Resectable Oesophageal or Oesophagogastric Junction Cancer. DRUGS, 71 (5). pp. 541-555. ISSN 0012-6667

Cunningham, D., Chong, I. (2010) Optimal treatment of metastatic pancreatic cancer. GUT, 59 (11). pp. 1454-1455. ISSN 0017-5749

Wong, R., Cunningham, D. (2009) Optimising treatment regimens for the management of advanced gastric cancer. ANNALS OF ONCOLOGY, 20 (4). pp. 605-608. ISSN 0923-7534

Yim, K., Cunningham, D. (2009) Optimizing irinotecan regimens for colorectal cancer. NATURE REVIEWS CLINICAL ONCOLOGY, 6 (10). pp. 560-561. ISSN 1759-4774

Cunningham, D., Maroun, J., Vanhoefer, U., Van Cutsem, E. (2001) Optimizing the use of irinotecan in colorectal cancer. Incorporating oral Capecitabine into the treatment of colorectal cancer. ONCOLOGIST, 6 (Supple). pp. 17-23. ISSN 1083-7159

Van Cutsem, E., Hoff, P. M., Harper, P., Bukowski, R. M., Cunningham, D., Dufour, P., Graeven, U., Lokich, J., Madajewicz, S., Maroun, J. A., Marshall, J. L., Mitchell, E. P., Perez-Manga, G., Rougier, P., Schmiegel, W., Schoelmerich, J., Sobrero, A., Schilsky, R. L. (2004) Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. BRITISH JOURNAL OF CANCER, 90 (6). pp. 1190-1197. ISSN 0007-0920

Chau, I., Cunningham, D. (2001) Overview: chemotherapy in the treatment of colorectal cancer. In: Progress in Colorectal Cancer 5: No 4. Mediscript Ltd., p. 25.

Tebbutt NC, Cunningham D. (2001) Overview: chemotherapy in the treatment of colorectal cancer. In: Progress in Colorectal Cancer 5: No.1. Mediscript Ltd., p. 24.

Allen M, Cunningham D. (2001) Overview: chemotherapy in the treatment of colorectal cancer. In: Progress in Colorectal Cancer 5: No 3. Mediscript Ltd., p. 24.

Sumpter, K., Harper-Wynne, C., Cunningham, D., Gillbanks, A., Norman, A. R., Hill, M. (2003) Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: A single institution's experience. CLINICAL ONCOLOGY, 15 (5). pp. 221-226. ISSN 0936-6555

Rahemtulla, Z., Baldwin, C., Spiro, A., McGough, C., Norman, A. R., Frost, G., Cunningham, D., Andreyev, H. J. N. (2005) The palatability of milk-based and non-milk-based nutritional supplements in gastrointestinal cancer and the effect of chemotherapy. CLINICAL NUTRITION, 24 (6). pp. 1029-1037. ISSN 0261-5614

Chua, Y. J., Cunningham, D. (2006) Panitumumab. DRUGS OF TODAY, 42 (11). pp. 711-719. ISSN 1699-3993

Douillard, J. Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., Rivera, F., Kocakova, I., Ruff, P., Blasinska-Morawiec, M., Smakal, M., Canon, J. L., Rother, M., Williams, R., Rong, A., Wiezorek, J., Sidhu, R., Patterson, S. D. (2013) Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 369 (11). pp. 1023-1034. ISSN 0028-4793

Rees, J., Hurt, C. N., Gollins, S., Mukherjee, S., Maughan, T., Falk, S. J., Staffurth, J., Ray, R., Bashir, N., Geh, J. I., Cunningham, D., Roy, R., Bridgewater, J., Griffiths, G., Nixon, L. S., Blazeby, J. M., Crosby, T. (2015) Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. BRITISH JOURNAL OF CANCER, 113 (4). pp. 603-610. ISSN 0007-0920

Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., Smith, D. B., Langley, R. E., Verma, M., Weeden, S., Chua, Y. J., MAGIC Trial Participants, [Group Author] (2006) Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 355 (1). pp. 11-20. ISSN 0028-4793

Okines, A., Sharma, B., Cunningham, D. (2010) Perioperative management of esophageal cancer. NATURE REVIEWS CLINICAL ONCOLOGY, 7 (4). pp. 231-238. ISSN 1759-4774

Jackson, C., Starling, N., Chua, Y. J., Cunningham, D. (2007) Pharmacotherapy for oesophagogastric cancer. DRUGS, 67 (17). pp. 2539-2556. ISSN 0012-6667

Odore, E., Lokiec, F., Cvitkovic, E., Bekradda, M., Herait, P., Bourdel, F., Kahatt, C., Raffoux, E., Stathis, A., Thieblemont, C., Quesnel, B., Cunningham, D., Riveiro, M. E., Rezai, K. (2016) Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. CLINICAL PHARMACOKINETICS, 55 (3). pp. 397-405. ISSN 0312-5963

Rao, S., Starling, N., Cunningham, D., Benson, M., Wotherspoon, A., Lupfert, C., Kurek, R., Oates, J., Baselga, J., Hill, A. (2008) Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. BRITISH JOURNAL OF CANCER, 99 (6). pp. 868-874. ISSN 0007-0920

Mackay, H. J., Hill, M., Twelves, C., Glasspool, R., Price, T., Campbell, S., Massey, A., Macham, M. A., Uzzel, M., Bailey, S. M., Martin, C., Cunningham, D. (2003) A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. ANNALS OF ONCOLOGY, 14 (8). pp. 1264-1269. ISSN 0923-7534

Rao, S., Cunningham, D., Price, T., Hill, M. E., Ross, P. J., Tebbutt, N., Norman, A. R., Oates, J., Shellito, P. (2004) Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. BRITISH JOURNAL OF CANCER, 91 (5). pp. 839-843. ISSN 0007-0920

Evans, T. R. J., Colston, K. W., Lofts, F. J., Cunningham, D., Anthoney, D. A., Gogas, H., de Bono, J. S., Hamberg, K. J., Skov, T., Mansi, J. L. (2002) A phase II trial of the vitamin D analogue Seocalcitol (EB 1089) in patients with inoperable pancreatic cancer. BRITISH JOURNAL OF CANCER, 86 (5). pp. 680-685. ISSN 0007-0920

Rao, S., Cunningham, D., de Gramont, A., Scheithauer, W., Smakal, M., Humblet, Y., Kourteva, G., Iveson, T., Andre, T., Dostalova, J., Illes, A., Belly, R., Perez-Ruixo, J. J., Park, Y. C., Palmer, P. A. (2004) Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 22 (19). pp. 3950-3957. ISSN 0732-183X

Rao, S., Cunningham, D., Hawkins, R. E., Hill, M. E., Smith, D., Daniel, F., Ross, P. J., Oates, J., Norman, A. R. (2005) Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. BRITISH JOURNAL OF CANCER, 92 (9). pp. 1650-1654. ISSN 0007-0920

Chong, G., Bhatnagar, A., Cunningham, D., Cosgriff, T. M., Harper, P. G., Steward, W., Bridgewater, J., Moore, M., Cassidy, J., Coleman, R., Coxon, F., Redfern, C. H., Jones, J. J., Hawkins, R., Northfelt, D., Sreedharan, S., Valone, F., Carmichael, J. (2006) Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. ANNALS OF ONCOLOGY, 17 (3). pp. 437-442. ISSN 0923-7534

Haller, D. G., Cassidy, J., Clarke, S. J., Cunningham, D., Van Cutsem, E., Hoff, P. M., Rothenberg, M. L., Saltz, L. B., Schmoll, H. J., Allegra, C., Bertino, J. R., Douillard, J. Y., Gustavsson, B. G., Milano, G., O'Connell, M., Rustum, Y., Tabernero, J., Gilberg, F., Sirzen, F., Twelves, C. (2008) Potential regional differences for the tolerability profiles of fluoropyrimidines. JOURNAL OF CLINICAL ONCOLOGY, 26 (13). pp. 2118-2123. ISSN 0732-183X

Waddell, T., Moorcraft, S. Y., Cunningham, D. (2014) Potential role of rilotumumab in the treatment of gastric cancer. Immunotherapy, 6 (12). pp. 1243-1253. ISSN 1750-743X

Asghar, U., Hawkes, E., Cunningham, D. (2010) Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer. CLINICAL COLORECTAL CANCER, 9 (5). pp. 274-281. ISSN 1533-0028

Mitry, E., Douillard, J. Y., Van Cutsem, E., Cunningham, D., Magherini, E., Mery-Mignard, D., Awad, L., Rougier, P. (2004) Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. ANNALS OF ONCOLOGY, 15 (7). pp. 1013-1017. ISSN 0923-7534

Neofytou, K., Smyth, E. C., Giakoustidis, A., Khan, A. Z., Williams, R., Cunningham, D., Mudan, S. (2015) The Preoperative Lymphocyte-to-Monocyte Ratio is Prognostic of Clinical Outcomes for Patients with Liver-Only Colorectal Metastases in the Neoadjuvant Setting. ANNALS OF SURGICAL ONCOLOGY, 22 (13). pp. 4353-4362. ISSN 1068-9265

Bruhn, M. A., Townsend, A. R., Lee, C. K., Shivasami, A., Price, T. J., Wrin, J., Arentz, G., Tebbutt, N. C., Hocking, C., Cunningham, D., Hardingham, J. E., AGITG, B. H. I. Collaboration (2014) Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. INTERNATIONAL JOURNAL OF CANCER, 135 (3). pp. 731-741. ISSN 0020-7136

Bridgewater, J., Lopes, A., Wasan, H., Malka, D., Jensen, L., Okusaka, T., Knox, J., Wagner, D., Cunningham, D., Shannon, J., Goldstein, D., Moehler, M., Bekaii-Saab, T., McNamara, M. G., Valle, J. W. (2016) Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. ANNALS OF ONCOLOGY, 27 (1). pp. 134-140. ISSN 0923-7534

Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., Aranda, E., Nordlinger, B., Cisar, L., Labianca, R., Cunningham, D., Van Cutsem, E., Bosman, F. (2010) Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. JOURNAL OF CLINICAL ONCOLOGY, 28 (3). pp. 466-474. ISSN 0732-183X

Formica, V., Wotherspoon, A., Cunningham, D., Norman, A. R., Sirohi, B., Oates, J., Chong, G. (2007) The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. BRITISH JOURNAL OF CANCER, 96 (8). pp. 1178-1182. ISSN 0007-0920

Ross, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., Price, T., Anderson, H., Iveson, T., Hickish, T., Lofts, F., Norman, A. (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PV1 5-FU) with epirubicin, cisplatin, and PV15-FU in advanced esophagogastric cancer. JOURNAL OF CLINICAL ONCOLOGY, 20 (8). pp. 1996-2004. ISSN 0732-183X

Van Cutsem, E., Cunningham, D., Maroun, J., Cervantes, A., Glimelius, B. (2002) Raltitrexed: current clinical status and future directions. ANNALS OF ONCOLOGY, 13 (4). pp. 513-522. ISSN 0923-7534

Wilke, H., Muro, K., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T. Y., Cunningham, D., Rougier, P., Komatsu, Y., Ajani, J., Emig, M., Carlesi, R., Ferry, D., Chandrawansa, K., Schwartz, J. D., Ohtsu, A., Rainbow Study, Grp (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. LANCET ONCOLOGY, 15 (11). pp. 1224-1235. ISSN 1470-2045

Assersohn, L., Norman, A. R., Cunningham, D., Iveson, T., Seymour, M., Hickish, T., Massey, A., Prior, Y., Hill, M. E. (2003) A randomised study of protracted venous infusion of 5- fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. EUROPEAN JOURNAL OF CANCER, 39 (8). pp. 1121-1128. ISSN 0959-8049

Roy, A. C., Park, S. R., Cunningham, D., Kang, Y. K., Chao, Y., Chen, L. T., Rees, C., Lim, H. Y., Tabernero, J., Ramos, F. J., Kujundzic, M., Cardic, M. B., Yeh, C. G., de Gramont, A. (2013) A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. ANNALS OF ONCOLOGY, 24 (6). pp. 1567-1573. ISSN 0923-7534

Sclafani, F., Kim, T. Y., Cunningham, D., Kim, T. W., Tabernero, J., Schmoll, H. J., Roh, J. K., Kim, S. Y., Park, Y. S., Guren, T. K., Hawkes, E., Clarke, S. J., Ferry, D., Frodin, J. E., Ayers, M., Nebozhyn, M., Peckitt, C., Loboda, A., Mauro, D. J., Watkins, D. J. (2015) A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 107 (12). p. 9. ISSN 0027-8874

Van Cutsem, E., Labianca, R., Bodoky, G., Barone, C., Aranda, E., Nordlinger, B., Topham, C., Tabernero, J., Andre, T., Sobrero, A. F., Mini, E., Greil, R., Di Costanzo, F., Collette, L., Cisar, L., Zhang, X., Khayat, D., Bokemeyer, C., Roth, A. D., Cunningham, D. (2009) Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. JOURNAL OF CLINICAL ONCOLOGY, 27 (19). pp. 3117-3125. ISSN 0732-183X

Lal, R., Dickson, J., Cunningham, D., Chau, I., Norman, A. R., Ross, P. J., Topham, C., Middleton, G., Hill, M., Oates, J. (2004) A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor- resistant advanced colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 22 (15). pp. 3023-3031. ISSN 0732-183X

Van Cutsem, E., Bang, Y. J., Mansoor, W., Petty, R. D., Chao, Y., Cunningham, D., Ferry, D. R., Smith, N. R., Frewer, P., Ratnayake, J., Stockman, P. K., Kilgour, E., Landers, D. (2017) A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. ANNALS OF ONCOLOGY, 28 (6). pp. 1316-1324. ISSN 0923-7534

Douillard, J., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., Rivera, F., Kocakova, I., Ruff, P., Blasinska-Morawiec, M., Smakal, M., Canon, J., Rother, M., Oliner, K. S., Wolf, M., Gansert, J. (2010) Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. JOURNAL OF CLINICAL ONCOLOGY, 28 (31). pp. 4697-4705. ISSN 0732-183X

Dewdney, A., Hawkes, E. A., Cunningham, D. (2011) Ras Inhibition and the Survival Benefit Favoring Zoledronic Acid Compared With Denosumab in Patients With Multiple Myeloma Reply. JOURNAL OF CLINICAL ONCOLOGY, 29 (19). pp. 2737-2738. ISSN 0732-183X

Sclafani, F., Cunningham, D., Peckitt, C., Watkins, D. (2016) RE: A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer RESPONSE. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 108 (3). ISSN 0027-8874

Hawkes, E., Cunningham, D. (2010) Relationship Between Colorectal Cancer Biomarkers and Response to Epidermal Growth Factor Receptor Monoclonal Antibodies. JOURNAL OF CLINICAL ONCOLOGY, 28 (28). E529-E531. ISSN 0732-183X

Linch, M., Cunningham, D., Mingo, O., Stiles, A., Farquhar-Smith, W. P. (2007) Renal tubular acidosis due to oxaliplatin. ANNALS OF ONCOLOGY, 18 (4). pp. 805-806. ISSN 0923-7534

Ross, P. J., Cunningham, D. (2003) Reply 2: NICE guidelines on drugs for colorectal cancer. BRITISH JOURNAL OF CANCER, 88 (7). pp. 1154-1155. ISSN 0007-0920

Davies, A. R., Gossage, J. A., Zylstra, J. L., Mattsson, F., Lagergren, J., Maisey, N., Smyth, E. C., Cunningham, D., Allum, W. H., Mason, R. C. (2015) Reply to RC Turkington et al. JOURNAL OF CLINICAL ONCOLOGY, 33 (9). 1089-+. ISSN 0732-183X

Chong, G., Cunningham, D. (2006) Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. BRITISH JOURNAL OF CANCER, 94 (6). p. 937. ISSN 0007-0920

Sumpter, K., Harper-Wynne, C., Cunningham, D., Rao, S., Tebbutt, N., Norman, A. R., Ward, C., Iveson, T., Nicolson, M., Hickish, T., Hill, M., Oates, J. (2005) Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. BRITISH JOURNAL OF CANCER, 92 (11). pp. 1976-1983. ISSN 0007-0920

Jackson, C., Cunningharn, D. (2007) A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: Impact on treatment of today's patients. CLINICAL BREAST CANCER, 7 (Supple). S8-S15. ISSN 1526-8209

Cunningham, D., Hawkes, E. A., Jack, A., Qian, W. D., Smith, P., Mouncey, P., Pocock, C., Ardeshna, K. M., Radford, J. A., McMillan, A., Davies, J., Turner, D., Kruger, A., Johnson, P., Gambell, J., Linch, D. (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. LANCET, 381 (9880). pp. 1817-1826. ISSN 0140-6736

Ardeshna, K. M., Qian, W. D., Smith, P., Braganca, N., Lowry, L., Patrick, P., Warden, J., Stevens, L., Pocock, C. F. E., Miall, F., Cunningham, D., Davies, J., Jack, A., Stephens, R., Walewski, J., Ferhanoglu, B., Bradstock, K., Linch, D. C. (2014) Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. LANCET ONCOLOGY, 15 (4). pp. 424-435. ISSN 1470-2045

Chong, G., Cunningham, D. (2005) The role of cetuximab in the therapy of previously treated advanced colorectal cancer. SEMINARS IN ONCOLOGY, 32 (6). S55-S58. ISSN 0093-7754

Watkins, D., Cunningham, D. (2007) The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancer. CLINICAL COLORECTAL CANCER, 6 (Supple). S47-S52. ISSN 1533-0028

Moorcraft, S. Y., Smyth, E. C., Cunningham, D. (2013) The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therapeutic Advances in Gastroenterology, 6 (5). pp. 381-395. ISSN 1756-283X

Chong, G., Cunningham, D. (2005) The role of preoperative chemotherapy for esophageal cancer: when is surgery alone feasible? NATURE CLINICAL PRACTICE ONCOLOGY, 2 (4). pp. 172-173. ISSN 1743-4254

Guppy, A. E., Tebbutt, N. C., Norman, A., Cunningham, D. (2003) The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. LEUKEMIA & LYMPHOMA, 44 (1). pp. 123-125. ISSN 1042-8194

Starling, N., Cunningham, D. (2006) The role of systemic therapy for localised gastric cancer. ANNALS OF ONCOLOGY, 17 (Supple). X115-X121. ISSN 0923-7534

Van Cutsem, E., Rivera, F., Berry, S., Kretzschmar, A., Michael, M., DiBartolomeo, M., Mazier, M. -., Canon, J. -., Georgoulias, V., Peeters, M., Bridgewater, J., Cunningham, D., First BEAT Investigators, [Group Author] (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. ANNALS OF ONCOLOGY, 20 (11). pp. 1842-1847. ISSN 0923-7534

Baldwin, C., Spiro, A., McGough, C., Norman, A. R., Gillbanks, A., Thomas, K., Cunningham, D., O'Brien, M., Andreyev, H. J. N. (2011) Simple nutritional intervention in patients with advanced cancers of the gastrointestinal tract, non-small cell lung cancers or mesothelioma and weight loss receiving chemotherapy: a randomised controlled trial. JOURNAL OF HUMAN NUTRITION AND DIETETICS, 24 (5). pp. 431-440. ISSN 0952-3871

Katopodis, O., Ross, P., Norman, A. R., Oates, J., Cunningham, D. (2004) Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden Hospital. EUROPEAN JOURNAL OF CANCER, 40 (15). pp. 2230-2236. ISSN 0959-8049

Tebbutt, N. C., Norman, A., Hill, M., Cunningham, D. (2001) Standard chemotherapy for gastric carcinoma: Is it a myth? JOURNAL OF CLINICAL ONCOLOGY, 19 (10). pp. 2765-2767. ISSN 0732-183X

Rao, S., Cunningham, D. (2008) Survival from cancer of the oesophagus in England and Wales up to 2001 - Clinical commentary. BRITISH JOURNAL OF CANCER, 99 (Supple). S14-S15. ISSN 0007-0920

Starling, N., Cunningham, D. (2008) Survival from cancer of the pancreas in England and Wales up to 2001 - Clinical commentary. BRITISH JOURNAL OF CANCER, 99 (Supple). S24-S25. ISSN 0007-0920

Rao, S., Cunningham, D. (2008) Survival from cancer of the stomach in England and Wales up to 2001 - Clinical commentary. BRITISH JOURNAL OF CANCER, 99 (Supple). S19-S20. ISSN 0007-0920

Khalid, U., Spiro, A., Baldwin, C., Sharma, B., McGough, C., Norman, A. R., Eisen, T., O'Brien, M. E. R., Cunningham, D., Andreyev, H. J. N. (2007) Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. SUPPORTIVE CARE IN CANCER, 15 (1). pp. 39-46. ISSN 0941-4355

Primrose, J., Falk, S., Finch-Jones, M., Valle, J., O'Reilly, D., Siriwardena, A., Hornbuckle, J., Peterson, M., Rees, M., Iveson, T., Hickish, T., Butler, R., Stanton, L., Dixon, E., Little, L., Bowers, M., Pugh, S., Garden, O. J., Cunningham, D., Maughan, T., Bridgewater, J. (2014) Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. LANCET ONCOLOGY, 15 (6). pp. 601-611. ISSN 1470-2045

Formica, V., Luccchetti, J., Cunningham, D., Smyth, E. C., Ferroni, P., Nardecchia, A., Tesauro, M., Cereda, V., Guadagni, F., Roselli, M. (2014) Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. MEDICAL ONCOLOGY, 31 (9). p. 8. ISSN 1357-0560

Tebbutt, N. C., Cattell, E., Midgley, R., Cunningham, D., Kerr, D. (2002) Systemic treatment of colorectal cancer. EUROPEAN JOURNAL OF CANCER, 38 (7). pp. 1000-1015. ISSN 0959-8049

Dickson, J. L. B., Cunningham, D. (2004) Systemic treatment of gastric cancer. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 16 (3). pp. 255-263. ISSN 0954-691X

Banerjee, S., Cunningham, D. (2010) Targeted Therapies as Adjuvant Treatment for Early-Stage Colorectal Cancer: First Impressions and Clinical Questions. CLINICAL COLORECTAL CANCER, 9 (Suppl.). S28-S35. ISSN 1533-0028

Smyth, E. C., Cunningham, D. (2012) Targeted Therapy for Gastric Cancer. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 13 (3). pp. 377-389. ISSN 1527-2729

Zhang, S., Tan, I. B., Sapari, N. S., Grabsch, H. I., Okines, A., Smyth, E. C., Aoyama, T., Hewitt, L. C., Inam, I., Bottomley, D., Nankivell, M., Stenning, S. P., Cunningham, D., Wotherspoon, A., Tsuburaya, A., Yoshikawa, T., Soong, R., Tan, P. (2015) Technical Reproducibility of Single-Nucleotide and Size-Based DNA Biomarker Assessment Using DNA Extracted from Formalin-Fixed, Paraffin-Embedded Tissues. JOURNAL OF MOLECULAR DIAGNOSTICS, 17 (3). pp. 242-250. ISSN 1525-1578

Jackson, C., Mochlinski, K., Cunningham, D. (2007) Therapeutic options in gastric cancer: Neoadjuvant chemotherapy vs postoperative chemoradiotherapy. ONCOLOGY-NEW YORK, 21 (9). pp. 1084-1087. ISSN 0890-9091

Sebag-Montefiore, D., Meadows, H. M., Cunningham, D., Plowman, P. N., Hurman, D. C., Davidson, N., Grieve, R., Levine, E., Glynne-Jones, R., Grp, Ncri Anal Canc Sub (2012) Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): Long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. RADIOTHERAPY AND ONCOLOGY, 104 (2). pp. 155-160. ISSN 0167-8140

Starling, N., Rao, S., Cunningham, D., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., Norman, A. R. (2009) Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. JOURNAL OF CLINICAL ONCOLOGY, 27 (23). pp. 3786-3793. ISSN 0732-183X

Van Cutsem, E., Cunningham, D., Hoff, P. M., Maroun, J. (2001) Thymidine phosphorylase (TP) activation: Convenience through innovation. ONCOLOGIST, 6 (Supple). pp. 1-2. ISSN 1083-7159

Negri, F. V., Azzoni, C., Bottarelli, L., Campanini, N., Mandolesi, A., Wotherspoon, A., Cunningham, D., Scartozzi, M., Cascinu, S., Tinelli, C., Silini, E. M., Ardizzoni, A. (2013) Thymidylate Synthase, Topoisomerase-1 and Microsatellite Instability: Relationship with Outcome in Mucinous Colorectal Cancer Treated with Fluorouracil. ANTICANCER RESEARCH, 33 (10). pp. 4611-4617. ISSN 0250-7005

Ruff, P., Ferry, D. R., Lakomy, R., Prausova, J., Van Hazel, G. A., Hoff, P. M., Cunningham, D., Arnold, D., Schmoll, H. J., Moiseyenko, V. M., McKendrick, J. J., ten Tije, A. J., Vishwanath, R. L., Bhargava, P., Chevalier, S., Macarulla, T., Van Cutsem, E. (2015) Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. EUROPEAN JOURNAL OF CANCER, 51 (1). pp. 18-26. ISSN 0959-8049

Dewdney, A., Cunningham, D. (2012) Toward the Non-surgical Management of Locally Advanced Rectal Cancer. Current Oncology Reports, 14 (3). pp. 267-276. ISSN 1523-3790

Sha, C. L., Barrans, S., Care, M. A., Cunningham, D., Tooze, R. M., Jack, A., Westhead, D. R. (2015) Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas. Genome Medicine, 7. ISSN 1756-994X

Okines, A. F. C., Cunningham, D. (2010) Trastuzumab in gastric cancer. EUROPEAN JOURNAL OF CANCER, 46 (11). pp. 1949-1959. ISSN 0959-8049

Cunningham, D., Allum, W. H., Stenning, S. P. (2006) Treatment of gastric cancer - Reply. NEW ENGLAND JOURNAL OF MEDICINE, 355 (13). pp. 1387-1388. ISSN 0028-4793

Davies, A. R., Gossage, J. A., Zylstra, J., Mattsson, F., Lagergren, J., Maisey, N., Smyth, E. C., Cunningham, D., Allum, W. H., Mason, R. C. (2014) Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction. JOURNAL OF CLINICAL ONCOLOGY, 32 (27). 2983-+. ISSN 0732-183X

Jones, R. L., Cunningham, D., Cook, G., Ell, P. J. (2004) Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes. BRITISH JOURNAL OF RADIOLOGY, 77 (913). pp. 74-75. ISSN 0007-1285

Glynne-Jones, R., Kadalayil, L., Meadows, H. M., Cunningham, D., Samuel, L., Geh, J. I., Lowdell, C., James, R., Beare, S., Begum, R., Ledermann, J. A., Sebag-Montefiore, D., Grp, Act Ii Study (2014) Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial. ANNALS OF ONCOLOGY, 25 (8). pp. 1616-1622. ISSN 0923-7534

Cunningham, D., Sirohi, B., Pluzanska, A., Utracka-Hutka, B., Zaluski, J., Glynne-Jones, R., Koralewski, P., Bridgewater, J., Mainwaring, P., Wasan, H., Wang, J. Y., Szczylik, C., Clingan, P., Chan, R. T. T., Tabah-Fisch, I., Cassidy, J. (2009) Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. ANNALS OF ONCOLOGY, 20 (2). pp. 244-250. ISSN 0923-7534

Chua, Y. J., Cunningham, D. (2007) The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: Implications for clinical practice. ANNALS OF SURGICAL ONCOLOGY, 14 (10). pp. 2687-2690. ISSN 1068-9265

Hawkes, E. A., Wotherspoon, A., Cunningham, D. (2012) The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management. LEUKEMIA & LYMPHOMA, 53 (3). pp. 354-361. ISSN 1042-8194

Wong, R., Cunningham, D. (2008) Using Predictive Biomarkers to Select Patients With Advanced Colorectal Cancer for Treatment With Epidermal Growth Factor Receptor Antibodies. JOURNAL OF CLINICAL ONCOLOGY, 26 (35). pp. 5668-5670. ISSN 0732-183X

Smith, C. T., Stocken, D. D., Dunn, J., Cox, T., Ghaneh, P., Cunningham, D., Neoptolemos, J. P. (2012) The Value of Source Data Verification in a Cancer Clinical Trial. PLOS ONE, 7 (12). ISSN 1932-6203

Wong, R., Cunningham, D. (2008) What is the impact of biologicals in colorectal cancer? TARGETED ONCOLOGY, 3 (2). pp. 59-69. ISSN 1776-2596

Chong, G., Cunningham, D. (2005) What is the role of mitomycin C in advanced gastric cancer? ONKOLOGIE, 28 (3). pp. 125-126. ISSN 0378-584X

Jackson, C., Cunningham, D. (2008) Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer. EUROPEAN JOURNAL OF CANCER, 44 (5). pp. 652-662. ISSN 0959-8049

Hewish, M., Lord, C. J., Martin, S. A., Cunningham, D., Ashworth, A. (2010) Mismatch repair deficient colorectal cancer in the era of personalized treatment. NATURE REVIEWS CLINICAL ONCOLOGY, 7 (4). pp. 197-208. ISSN 1759-4774

Balyasnikova, S., Haboubi, N., Wale, A., Santiago, I., Morgan, M., Cunningham, D., Mason, M., Berho, M., Brown, G. (2018) Session 2: Extramural vascular invasion and extranodal deposits: should they be treated the same? COLORECTAL DISEASE, 20. pp. 43-48. ISSN 1462-8910

O'Neill, B. D. P., Brown, G., Cunningham, D., Heald, R. J., Tait, D. M. (2007) Chemoradiotherapy alone for rectal cancer: A word of caution - Reply. LANCET ONCOLOGY, 8 (10). pp. 862-863. ISSN 1470-2045

Bhangu, A., Ali, S. M., Cunningham, D., Brown, G., Tekkis, P. (2013) Comparison of long-term survival outcome of operative vs nonoperative management of recurrent rectal cancer. COLORECTAL DISEASE, 15 (2). pp. 156-163. ISSN 1462-8910

Bhangu, A., Rasheed, S., Brown, G., Tait, D., Cunningham, D., Tekkis, P. (2014) Does rectal cancer height influence the oncological outcome? COLORECTAL DISEASE, 16 (10). pp. 801-808. ISSN 1462-8910

Burton, S., Brown, G., Daniels, I. R., Norman, A. R., Mason, B., Cunningham, D., Colorectal Cancer Network, [Group Author] (2006) MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins? BRITISH JOURNAL OF CANCER, 94 (3). pp. 351-357. ISSN 0007-0920

O'Neill, B. D. P., Brown, G., Heald, R. J., Cunningham, D., Tait, D. M. (2007) Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. LANCET ONCOLOGY, 8 (7). pp. 625-633. ISSN 1470-2045

Leary, A., Assersohn, L., Cunningham, D., Norman, A. R., Chong, G., Brown, G., Ross, P. J., Costello, C., Higgins, L., Oates, J. (2009) A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 64 (3). pp. 455-462. ISSN 0344-5704

Sclafani, F., Gonzalez, D., Cunningham, D., Wilson, S. H., Peckitt, C., Tabernero, J., Glimelius, B., Cervantes, A., Dewdney, A., Wotherspoon, A., Brown, G., Tait, D., Oates, J., Chau, I. (2014) TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 106 (7). p. 4. ISSN 0027-8874

Watkins, D. J., Chau, I., Cunningham, D., Mudan, S. S., Karanjia, N., Brown, G., Ashley, S., Norman, A. R., Gillbanks, A. (2010) Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. BRITISH JOURNAL OF CANCER, 102 (2). pp. 255-261. ISSN 0007-0920

Sclafani, F., Gonzalez, D., Cunningham, D., Wilson, S. H., Peckitt, C., Giralt, J., Glimelius, B., Keranen, S. R., Wotherspoon, A., Brown, G., Tait, D., Oates, J., Chau, I. (2014) RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial. EUROPEAN JOURNAL OF CANCER, 50 (8). pp. 1430-1436. ISSN 0959-8049

Chau, I., Cunningham, D., Tait, D., Brown, G. (2006) Role of neoadjuvant chemotherapy in rectal cancer: Interpretation of the EXPERT study - Reply. JOURNAL OF CLINICAL ONCOLOGY, 24 (28). pp. 4665-4666. ISSN 0732-183X

Chau, I., Allen, M. J., Cunningham, D., Norman, A. R., Brown, G., Ford, H. E. R., Tebbutt, N., Tait, D., Hill, M., Ross, P. J., Oates, J. (2004) The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 22 (8). pp. 1420-1429. ISSN 0732-183X

Tekkis, P., Tait, D., Cunningham, D., Brown, G. (2018) Is organ preservation in rectal cancer ready for prime time? LANCET, 391 (10139). pp. 2480-2482. ISSN 0140-6736

Gujral, D. M., Hawkins, M. A., Leonulli, B. G., Ashley, S., Chau, I., Cunningham, D., Tait, D. (2011) Nonsurgical Management of Esophageal Adenocarcinoma. CLINICAL COLORECTAL CANCER, 10 (3). pp. 165-170. ISSN 1533-0028

Gleeson, M., Peckitt, C., To, Y. M., Edwards, L., Oates, J., Wotherspoon, A., Attygalle, A. D., Zerizer, I., Sharma, B., Chua, S., Begum, R., Chau, I., Johnson, P., Ardeshna, K. M., Hawkes, E. A., Macheta, M. P., Collins, G. P., Radford, J., Forbes, A., Hart, A., Montoto, S., McKay, P., Benstead, K., Morley, N., Kalakonda, N., Hasan, Y., Turner, D., Cunningham, D. (2018) CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. LANCET HAEMATOLOGY, 5 (5). E190-E200. ISSN 2352-3026

Smyth, E. C., Tarazona, N., Peckitt, C., Armstrong, E., Mansukhani, S., Cunningham, D., Chau, I. (2016) Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified? CLINICAL COLORECTAL CANCER, 15 (2). E53-E59. ISSN 1533-0028

Fontana, E., Smyth, E. C., Cunningham, D., Rao, S., Watkins, D., Allum, W. H., Thompson, J., Waddell, T., Peckitt, C., Chau, I., Starling, N. (2016) Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010. Gastric Cancer, 19 (4). pp. 1114-1124. ISSN 1436-3291

Gleeson, M., Peckitt, C., Cunningham, D., Gibb, A., Hawkes, E. A., Back, M., Yasar, B., Foley, K., Lee, R., Dash, J., Johnson, H., O'Hara, C., Wotherspoon, A., Attygalle, A., Menasce, L., Shenjere, P., Potter, M., Ethell, M. E., Dearden, C., Radford, J., Chau, I., Linton, K. (2018) Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. LEUKEMIA & LYMPHOMA, 59 (7). pp. 1586-1595. ISSN 1042-8194

Sclafani, F., Brown, G., Cunningham, D., Wotherspoon, A., Tait, D., Peckitt, C., Evans, J., Yu, S., Mendes, L. S. T., Tabernero, J., Glimelius, B., Cervantes, A., Thomas, J., Begum, R., Oates, J., Chau, I. (2016) PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. ANNALS OF ONCOLOGY, 27 (8). pp. 1557-1565. ISSN 0923-7534

Khan, K., Athauda, A., Aitken, K., Cunningham, D., Watkins, D., Starling, N., Cook, G. J., Kalaitzaki, E., Chau, I., Rao, S. (2016) Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging. ONCOLOGIST, 21 (12). pp. 1502-1508. ISSN 1083-7159

Khan, K., Cunningham, D., Chau, I. (2017) Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions. CURRENT DRUG TARGETS, 18 (1). pp. 56-71. ISSN 1389-4501

Chau, I., Cunningham, D. (2006) Adjuvant therapy in colon cancer - what, when and how? ANNALS OF ONCOLOGY, 17 (9). pp. 1347-1359. ISSN 0923-7534

Tebbutt, N. C., Norman, A. R., Cunningham, D., Allen, M., Chau, I., Oates, J., Hill, M. (2003) Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil. BRITISH JOURNAL OF CANCER, 88 (10). pp. 1510-1515. ISSN 0007-0920

Chau, I., Cunningham, D. (2009) Bevacizumab-associated gastrointestinal perforation. LANCET ONCOLOGY, 10 (6). pp. 534-536. ISSN 1470-2045

Okines, A., Chau, I., Cunningham, D. (2007) Capecitabine in advanced gastric cancer. EXPERT OPINION ON PHARMACOTHERAPY, 8 (16). pp. 2851-2861. ISSN 1465-6566

Chau, I., Cunningham, D. (2004) Cetuximab in colon cancer - Reply. NEW ENGLAND JOURNAL OF MEDICINE, 351 (15). p. 1576. ISSN 0028-4793

Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., Chau, I., Van Cutsem, E. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. NEW ENGLAND JOURNAL OF MEDICINE, 351 (4). pp. 337-345. ISSN 0028-4793

Moorcraft, S. Y., Fontana, E., Cunningham, D., Peckitt, C., Waddell, T., Smyth, E. C., Allum, W., Thompson, J., Rao, S., Watkins, D., Starling, N., Chau, I. (2016) Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study. BMC CANCER, 16. ISSN 1471-2407

Chau, I., Cunningham, D. (2002) Chemotherapy in colorectal cancer: new options and new challenges. BRITISH MEDICAL BULLETIN, 64. pp. 159-180. ISSN 0007-1420

Chau, I., Cunningham, D. (2002) Cyclooxygenase inhibition in cancer - A blind alley or a new therapeutic reality? NEW ENGLAND JOURNAL OF MEDICINE, 346 (14). pp. 1085-1087. ISSN 0028-4793

Hawkes, E., Okines, A. F. C., Papamichael, D., Rao, S., Ashley, S., Charalambous, H., Koukouma, A., Chau, I., Cunningham, D. (2011) Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. EUROPEAN JOURNAL OF CANCER, 47 (8). pp. 1146-1151. ISSN 0959-8049

Chau, I., Norman, A. R., Cunningham, D., Waters, J. S., Topham, C., Middleton, G., Hill, M., Ross, P. J., Katopodis, R., Stewart, G., Oates, J. R. (2004) Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. BRITISH JOURNAL OF CANCER, 91 (8). pp. 1453-1458. ISSN 0007-0920

Okines, A. F. C., Ashley, S. E., Cunningham, D., Oates, J., Turner, A., Webb, J., Saffery, C., Chua, Y. J., Chau, I. (2010) Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial. JOURNAL OF CLINICAL ONCOLOGY, 28 (25). pp. 3945-3950. ISSN 0732-183X

Chau, I., Cunningham, D., Russell, C., Norman, A. R., Kurzawinski, T., Harper, P., Harrison, P., Middleton, G., Daniels, F., Hickish, T., Prendeville, J., Ross, P. J., Theis, B., Hull, R., Walker, M., Shankley, N., Kalindjian, B., Murray, G., Gillbanks, A., Black, J. (2006) Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. BRITISH JOURNAL OF CANCER, 94 (8). pp. 1107-1115. ISSN 0007-0920

Chau, I., Cunningham, D., Hickish, T., Massey, A., Higgins, L., Osborne, R., Botwood, N., Swaisland, A. (2007) Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. ANNALS OF ONCOLOGY, 18 (4). pp. 730-737. ISSN 0923-7534

Hubner, R. A., Worsnop, F., Cunningham, D., Chau, I. (2013) Gemcitabine Plus Capecitabine in Unselected Patients With Advanced Pancreatic Cancer. PANCREAS, 42 (3). pp. 511-515. ISSN 0885-3177

Sclafani, F., Roy, A., Cunningham, D., Wotherspoon, A., Peckitt, C., de Castro, D. G., Tabernero, J., Glimelius, B., Cervantes, A., Eltahir, Z., Oates, J., Chau, I. (2013) HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. ANNALS OF ONCOLOGY, 24 (12). pp. 3123-3128. ISSN 0923-7534

Chau, I., Norman, A. R., Cunningham, D., Oates, J., Hawkins, R., Iveson, T., Nicolson, M., Harper, P., Seymour, M., Hickish, T. (2009) The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma-025EFindividual patient data from 1775 patients in four randomised controlled trials. ANNALS OF ONCOLOGY, 20 (5). pp. 885-891. ISSN 0923-7534

Yau, T., Watkins, D., Cunningham, D., Barbachano, Y., Chau, I., Chong, G. (2009) Longitudinal Assessment of Quality of Life in Rectal Cancer Patients With or Without Stomas Following Primary Resection. DISEASES OF THE COLON & RECTUM, 52 (4). pp. 669-677. ISSN 0012-3706

Chau, I., Norman, A. R., Cunningham, D., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., Webb, A., Tait, D., Ross, P. J., Shellito, P., Oates, J. R. (2005) Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. EUROPEAN JOURNAL OF CANCER, 41 (11). pp. 1551-1559. ISSN 0959-8049

Chau, I., Rigg, A., Cunningham, D. (2003) Matrix metalloproteinase inhibitors - an emphasis on gastrointestinal malignancies. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 45 (2). pp. 151-176. ISSN 1040-8428

Arkenau, H. T., Gordon, C., Cunningham, D., Norman, A., Wotherspoon, A., Chau, I. (2007) Mucosa associated lymphoid tissue lymphoma of the lung: The Royal Marsden Hospital experience. LEUKEMIA & LYMPHOMA, 48 (3). pp. 547-550. ISSN 1042-8194

Maisey, N., Chau, I., Cunningham, D., Norman, A., Seymour, M., Hickish, T., Iveson, T., O'Brien, M., Tebbutt, N., Harrington, A., Hill, M. (2002) Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI5-FU plus mitomycin in inoperable pancreatic cancer. JOURNAL OF CLINICAL ONCOLOGY, 20 (14). pp. 3130-3136. ISSN 0732-183X

Chau, I., Webb, A., Cunningham, D., Hill, M., Waters, J. S., Norman, A., Massey, A. (2001) Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. BRITISH JOURNAL OF CANCER, 85 (9). pp. 1258-1264. ISSN 0007-0920

Chau, I., Cunningham, D. (2003) Oxaliplatin for colorectal cancer in the United States: better late than never. JOURNAL OF CLINICAL ONCOLOGY, 21 (11). pp. 2049-2051. ISSN 0732-183X

Young, K., Iyer, R., Morganstein, D., Chau, I., Cunningham, D., Starling, N. (2015) Pancreatic neuroendocrine tumors: a review. FUTURE ONCOLOGY, 11 (5). pp. 853-864. ISSN 1479-6694

Moorcraft, S. Y., Marriott, C., Peckitt, C., Cunningham, D., Chau, I., Starling, N., Watkins, D., Rao, S. (2016) Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. TRIALS, 17. ISSN 1745-6215

Constantinidou, A., Cunningham, D., Shurmahi, F., Asghar, U., Barbachano, Y., Khan, A., Mudan, S., Rao, S., Chau, I. (2013) Perioperative Chemotherapy With or Without Bevacizumab in Patients With Metastatic Colorectal Cancer Undergoing Liver Resection. CLINICAL COLORECTAL CANCER, 12 (1). pp. 15-22. ISSN 1533-0028

Starling, N., Vazquez-Mazon, F., Cunningham, D., Chau, I., Tabernero, J., Ramos, F. J., Iveson, T. J., Saunders, M. P., Aranda, E., Countouriotis, A. M., Ruiz-Garcia, A., Wei, G., Tursi, J. M., Guillen-Ponce, C., Carrato, A. (2012) A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. ANNALS OF ONCOLOGY, 23 (1). 119-U110. ISSN 0923-7534

Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D., Steward, W., Harper, P. G., Dunn, J., Tudur-Smith, C., West, J., Falk, S., Crellin, A., Adab, F., Thompson, J., Leonard, P., Ostrowski, J., Eatock, M., Scheithauer, W., Herrmann, R., Neoptolemos, J. P. (2009) Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. JOURNAL OF CLINICAL ONCOLOGY, 27 (33). pp. 5513-5518. ISSN 0732-183X

Chau, I., Norman, A. R., Cunningham, D., Tait, D., Ross, P. J., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., Webb, A., Oates, J. R. (2005) A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. ANNALS OF ONCOLOGY, 16 (4). pp. 549-557. ISSN 0923-7534

Okines, A., Del Puerto, O., Cunningham, D., Chau, I., Van Cutsem, E., Saltz, L., Cassidy, J. (2009) Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. BRITISH JOURNAL OF CANCER, 101 (7). pp. 1033-1038. ISSN 0007-0920

Okines, A., Cunningham, D., Chau, I. (2011) Targeting the human EGFR family in esophagogastric cancer. NATURE REVIEWS CLINICAL ONCOLOGY, 8 (8). pp. 492-503. ISSN 1759-4774

Chau, I., Cunningham, D. (2009) Treatment in advanced colorectal cancer: what, when and how? BRITISH JOURNAL OF CANCER, 100 (11). pp. 1704-1719. ISSN 0007-0920

Saini, A., Norman, A. R., Cunningham, D., Chau, I., Hill, M., Tait, D., Hickish, T., Iveson, T., Lofts, F., Jodrell, D., Ross, P. J., Oates, J. (2003) Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. BRITISH JOURNAL OF CANCER, 88 (12). pp. 1859-1865. ISSN 0007-0920

Hawkes, E., Chau, I., Ilson, D. H., Cunningham, D. (2009) Upper Gastrointestinal Malignancies: A New Era in Clinical Colorectal Cancer. CLINICAL COLORECTAL CANCER, 8 (4). pp. 185-189. ISSN 1533-0028

Chau, I., Ashley, S., Cunningham, D. (2009) Validation of the Royal Marsden Hospital Prognostic Index in Advanced Esophagogastric Cancer Using Individual Patient Data From the REAL 2 Study. JOURNAL OF CLINICAL ONCOLOGY, 27 (19). E3-E4. ISSN 0732-183X

Hawkes, E. A., Cunningham, D., Tait, D., Brown, G., Chau, I. (2011) Neoadjuvant Chemotherapy Alone for Early-Stage Rectal Cancer: An Evolving Paradigm? SEMINARS IN RADIATION ONCOLOGY, 21 (3). pp. 196-202. ISSN 1053-4296

Sclafani, F., Peckitt, C., Cunningham, D., Tait, D., Giralt, J., Glimelius, B., Keranen, S. R., Bateman, A., Hickish, T., Tabernero, J., Thomas, J., Brown, G., Oates, J., Chau, I. (2015) Short-and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93 (2). pp. 303-312. ISSN 0360-3016

Sclafani, F., Brown, G., Cunningham, D., Rao, S., Tekkis, P., Tait, D., Morano, F., Baratelli, C., Kalaitzaki, E., Rasheed, S., Watkins, D., Starling, N., Wotherspoon, A., Chau, I. (2017) Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. ONCOLOGIST, 22 (6). pp. 728-736. ISSN 1083-7159

Chau, I., Webb, A., Cunningham, D., Hill, M., Rao, S., Ageli, S., Norman, A., Gill, K., Howard, A., Catovsky, D. (2001) An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hogdkin's lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 115 (4). pp. 786-792. ISSN 0007-1048

Gleeson, M., Hawkes, E. A., Peckitt, C., Wotherspoon, A., Attygalle, A., Sharma, B., Du, Y., Ethell, M., Potter, M., Dearden, C., Horwich, A., Chau, I., Cunningham, D. (2017) Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013. LEUKEMIA & LYMPHOMA, 58 (8). pp. 1805-1813. ISSN 1042-8194

Sclafani, F., Morano, F., Cunningham, D., Baratelli, C., Kalaitzaki, E., Watkins, D., Starling, N., Chau, I., Rao, S. (2017) Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. ONCOLOGIST, 22 (4). pp. 402-408. ISSN 1083-7159

Khan, K. H., Cunningham, D., Werner, B., Vlachogiannis, G., Spiteri, I., Heide, T., Mateos, J. F., Vatsiou, A., Lampis, A., Damavandi, M. D., Lote, H., Huntingford, I. S., Hedayat, S., Chau, I., Tunariu, N., Mentrasti, G., Trevisani, F., Rao, S., Anandappa, G., Watkins, D., Starling, N., Thomas, J., Peckitt, C., Khan, N., Rugge, M., Begum, R., Hezelova, B., Bryant, A., Jones, T., Proszek, P., Fassan, M., Hahne, J. C., Hubank, M., Braconi, C., Sottoriva, A., Valeri, N. (2018) Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. CANCER DISCOVERY, 8 (10). pp. 1270-1285. ISSN 2159-8274

Sclafani, F., Brown, G., Cunningham, D., Wotherspoon, A., Mendes, L. S. T., Balyasnikova, S., Evans, J., Peckitt, C., Begum, R., Tait, D., Tabernero, J., Glimelius, B., Rosello, S., Thomas, J., Oates, J., Chau, I. (2017) Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. BRITISH JOURNAL OF CANCER, 117 (10). pp. 1478-1485. ISSN 0007-0920

Sclafani, F., Chau, I., Cunningham, D., Hahne, J. C., Vlachogiannis, G., Eltahir, Z., Lampis, A., Braconi, C., Kalaitzaki, E., De Castro, D. G., Wotherspoon, A., Capdevila, J., Glimelius, B., Tarazona, N., Begum, R., Lote, H., Wilson, S. H., Mentrasti, G., Brown, G., Tait, D., Oates, J., Valeri, N. (2018) KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. SCIENTIFIC REPORTS, 8. ISSN 2045-2322

Sclafani, F., Chau, I., Cunningham, D., Peckitt, C., Lampis, A., Hahne, J. C., Braconi, C., Tabernero, J., Glimelius, B., Cervantes, A., Begum, R., De Castro, D. G., Wilson, S. H., Eltahir, Z., Wotherspoon, A., Tait, D., Brown, G., Oates, J., Valeri, N. (2015) Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. ANNALS OF ONCOLOGY, 26 (9). pp. 1936-1941. ISSN 0923-7534

Sundar, R., Miranda, S., Rodrigues, D. N., Chenard-Poirier, M., Dolling, D., Clarke, M., Figueiredo, I., Bertan, C., Yuan, W., Ferreira, A., Chistova, R., Boysen, G., Perez, D. R., Tunariu, N., Mateo, J., Wotherspoon, A., Chau, I., Cunningham, D., Valeri, N., Carreira, S., de Bono, J. (2018) Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. CLINICAL COLORECTAL CANCER, 17 (4). pp. 280-284. ISSN 1533-0028

Cooke, R., Jones, M. E., Cunningham, D., Falk, S. J., Gilson, D., Hancock, B. W., Harris, S. J., Horwich, A., Hoskin, P. J., Illidge, T., Linch, D. C., Lister, T. A., Lucraft, H. H., Radford, J. A., Stevens, A. M., Syndikus, I., Williams, M. V., Swerdlow, A. J., England Wales Hodgkin, Lymphoma (2013) Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. BRITISH JOURNAL OF CANCER, 108 (11). pp. 2399-2406. ISSN 0007-0920

Hawkes, E. A., Barton, S., Cunningham, D., Peckitt, C., Chua, S., Wotherspoon, A., Horwich, A., Potter, M., Ethel, M., Dearden, C., Chau, I. (2014) GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. ANNALS OF HEMATOLOGY, 93 (5). pp. 827-834. ISSN 0939-5555

Barton, S., Hawkes, E. A., Cunningham, D., Peckitt, C., Chua, S., Wotherspoon, A., Attygalle, A., Horwich, A., Potter, M., Ethell, M., Dearden, C., Gleeson, M., Chau, I. (2015) Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma. EUROPEAN JOURNAL OF HAEMATOLOGY, 94 (3). pp. 219-226. ISSN 0902-4441

Khan, K., Ang, J. E., Starling, N., Sclafani, F., Shah, K., Judson, I., Molife, L. R., Banerji, U., de Bono, J. S., Cunningham, D., Kaye, S. B. (2014) Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. Gastric Cancer, 17 (4). pp. 621-629. ISSN 1436-3291

Kong, G., Jackson, C., Koh, D. M., Lewington, V., Sharma, B., Brown, G., Cunningham, D., Cook, G. J. R. (2008) The use of F-18-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 35 (7). pp. 1323-1329. ISSN 1619-7070

Koh, D. M., Chau, I., Tait, D., Wotherspoon, A., Cunningham, D., Brown, G. (2008) Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 71 (2). pp. 456-461. ISSN 0360-3016

Okines, A. F. C., Thompson, L. C., Cunningham, D., Wotherspoon, A., Reis, J. S., Langley, R. E., Waddell, T. S., Noor, D., Eltahir, Z., Wong, R., Stenning, S. (2013) Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. ANNALS OF ONCOLOGY, 24 (5). pp. 1253-1261. ISSN 0923-7534

Sheri, A., Smith, I. E., Johnston, S. R., A'Hern, R., Nerurkar, A., Jones, R. L., Hills, M., Detre, S., Pinder, S. E., Symmans, W. F., Dowsett, M. (2015) Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. ANNALS OF ONCOLOGY, 26 (1). pp. 75-80. ISSN 0923-7534

Athauda, A., Watkins, D., Mohammed, K., Chau, I., Starling, N., Rao, S., Tait, D., Aitken, K., Cunningham, D. (2018) Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre. ANTICANCER RESEARCH, 38 (10). pp. 5943-5949. ISSN 0250-7005

Davidson, M., Chau, I., Cunningham, D., Khabra, K., Iveson, T., Hickish, T., Seymour, M., Starling, N. (2017) Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 9 (8). pp. 333-340. ISSN 1948-5204

Young, K., Starling, N., Cunningham, D. (2016) Targeting deficient DNA damage repair in gastric cancer. EXPERT OPINION ON PHARMACOTHERAPY, 17 (13). pp. 1757-1766. ISSN 1465-6566

Flynn, M., Young, K., Cunningham, D., Starling, N. (2018) The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 10. pp. 1-17. ISSN 1758-8340

Smyth, E. C., Wotherspoon, A., Peckitt, C., Gonzalez, D., Hulkki-Wilson, S., Eltahir, Z., Fassan, M., Rugge, M., Valeri, N., Okines, A., Hewish, M., Allum, W., Stenning, S., Nankivell, M., Langley, R., Cunningham, D. (2017) Mismatch Repair Deficiency, Microsatellite Instability, and Survival An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA ONCOLOGY, 3 (9). pp. 1197-1203. ISSN 2374-2437

Sclafani, F., Chau, I., Cunningham, D., Lampis, A., Hahne, J. C., Ghidini, M., Lote, H., Zito, D., Tabernero, J., Glimelius, B., Cervantes, A., Begum, R., De Castro, D. G., Wilson, S. H., Peckitt, C., Eltahir, Z., Wotherspoon, A., Tait, D., Brown, G., Oates, J., Braconi, C., Valeri, N. (2016) Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. CARCINOGENESIS, 37 (9). pp. 852-857. ISSN 0143-3334

Rao, S., Welsh, L., Cunningham, D., Te-Poele, R. H., Benson, M., Norman, A., Saffery, C., Giddings, I., Workman, P., Clarke, P. A. (2011) Correlation of Overall Survival With Gene Expression Profiles in a Prospective Study of Resectable Esophageal Cancer. CLINICAL COLORECTAL CANCER, 10 (1). pp. 48-56. ISSN 1533-0028

Watkins, D. J., Starling, N., Cunningham, D., Thomas, J., Webb, J., Brown, G., Barbachano, Y., Oates, J., Chau, I. (2014) The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. EUROPEAN JOURNAL OF CANCER, 50 (8). pp. 1422-1429. ISSN 0959-8049

Dewdney, A., Cunningham, D., Barbachano, Y., Chau, I. (2012) Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. BRITISH JOURNAL OF CANCER, 106 (11). pp. 1718-1721. ISSN 0007-0920

Dewdney, A., Cunningham, D., Chau, I. (2013) Selecting Patients With Locally Advanced Rectal Cancer for Neoadjuvant Treatment Strategies. ONCOLOGIST, 18 (7). pp. 833-842. ISSN 1083-7159

Ford, H. E. R., Marshall, A., Bridgewater, J. A., Janowitz, T., Coxon, F. Y., Wadsley, J., Mansoor, W., Fyfe, D., Madhusudan, S., Middleton, G. W., Swinson, D., Falk, S., Chau, I., Cunningham, D., Kareclas, P., Cook, N., Blazeby, J. M., Dunn, J. A., Investigators, Cougar- (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. LANCET ONCOLOGY, 15 (1). pp. 78-86. ISSN 1470-2045

Moorcraft, S. Y., Khan, K., Peckitt, C., Watkins, D., Rao, S., Cunningham, D., Chau, I. (2014) FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience. CLINICAL COLORECTAL CANCER, 13 (4). pp. 232-238. ISSN 1533-0028

Hawkes, E. A., Ladas, G., Cunningham, D., Nicholson, A. G., Wassilew, K., Barbachano, Y., Ratnayake, G., Rao, S., Chau, I. (2012) Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases. BMC CANCER, 12. ISSN 1471-2407

Jain, V. K., Bystricky, B., Wotherspoon, A. C., Chau, I., Cunningham, D. (2012) Primary Follicular Lymphoma of the GI Tract: An Increasingly Recognized Entity. JOURNAL OF CLINICAL ONCOLOGY, 30 (36). E370-E372. ISSN 0732-183X

Tam, H. H., Cook, G. J., Chau, I., Drake, B., Zerizer, I., Du, Y., Cunningham, D., Koh, D. M., Chua, S. S. C. (2015) The Role of Routine Clinical Pretreatment F-18-FDG PET/CT in Predicting Outcome of Colorectal Liver Metastasis. CLINICAL NUCLEAR MEDICINE, 40 (5). E259-E264. ISSN 0363-9762

D

Heald, R. J., O'Neill, B. D. P., Moran, B., Brown, G., Darzi, A. W., Wotherspoon, A. C., Cunningham, D., Tait, D. M. (2006) MRI in predicting curative resection of rectal cancer - New dilemma in multidisciplinary team management. BRITISH MEDICAL JOURNAL, 333 (7572). p. 808. ISSN 0007-1447

McNair, H. A., Wedlake, L., McVey, G. P., Thomas, K., Andreyev, J., Dearnaley, D. P. (2011) Can diet combined with treatment scheduling achieve consistency of rectal filling in patients receiving radiotherapy to the prostate? RADIOTHERAPY AND ONCOLOGY, 101 (3). pp. 471-478. ISSN 0167-8140

Andreyev, H. J. N., Vlavianos, P., Blake, P., Dearnaley, D., Norman, A. R., Tait, D. (2005) Gastrointestinal symptoms after pelvic radiotherapy: Role for the gastroenterologist?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 62 (5). pp. 1464-1471. ISSN 0360-3016

Olopade, F. A., Norman, A., Blake, P., Dearnaley, D. P., Harrington, K. J., Khoo, V., Tait, D., Hackett, C., Andreyev, H. J. N. (2005) A modified Inflammatory Bowel Disease questionnaire and the Vaizey Incontinence questionnaire are simple ways to identify patients with significant gastrointestinal symptoms after pelvic radiotherapy. BRITISH JOURNAL OF CANCER, 92 (9). pp. 1663-1670. ISSN 0007-0920

Georgiou, P. A., Tekkis, P. P., Constantinides, V. A., Patel, U., Goldin, R. D., Darzi, A. W., Nicholls, R. J., Brown, G. (2013) Diagnostic accuracy and value of magnetic resonance imaging (MRI) in planning exenterative pelvic surgery for advanced colorectal cancer. EUROPEAN JOURNAL OF CANCER, 49 (1). pp. 72-81. ISSN 0959-8049

Spiteri, A. V., Aggarwal, R., Kersey, T. L., Sira, M., Benjamin, L., Darzi, A. W., Bloom, P. A. (2014) Development of a virtual reality training curriculum for phacoemulsification surgery. Eye, 28 (1). pp. 78-84. ISSN 0950-222X

E

George, M. L., Dzik-Jurasz, A. S. K., Padhani, A. R., Brown, G., Husband, J., Hill, M. E., Cunningham, D., Tait, D. M., Swift, R. I., Eccles, S. A. (2001) Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. BRITISH JOURNAL OF SURGERY, 88 (12). pp. 1628-1636. ISSN 0007-1323

G

Khakoo, S., Georgiou, A., Gerlinger, M., Cunningham, D., Starling, N. (2018) Circulating tumour DNA, a promising biomarker for the management of colorectal cancer. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 122. pp. 72-82. ISSN 1040-8428

Mansukhani, S., Barber, L. J., Kleftogiannis, D., Moorcraft, S. Y., Davidson, M., Woolston, A., Proszek, P. Z., Griffiths, B., Fenwick, K., Herman, B., Matthews, N., O'Leary, B., Hulkki, S., De Castro, D. G., Patel, A., Wotherspoon, A., Okachi, A., Rana, I., Begum, R., Davies, M. N., Powles, T., von Loga, K., Hubank, M., Turner, N., Watkins, D., Chau, I., Cunningham, D., Lise, S., Starling, N., Gerlinger, M. (2018) Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. CLINICAL CHEMISTRY, 64 (11). pp. 1626-1635. ISSN 0009-9147

Gore, M. E., Bellmunt, J., Eisen, T., Escudier, B., Mickisch, G., Patard, J., Porta, C., Ravaud, A., Schmidinger, M., Schoffski, P., Sternberg, C. N., Szczylik, C., De Nigris, E., Wheeler, C., Kirpekar, S. (2012) Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology. EUROPEAN JOURNAL OF CANCER, 48 (7). pp. 1038-1047. ISSN 0959-8049

Neves, M. C., Neofytou, K., Giakoustidis, A., Hazell, S., Wotherspoon, A., Gore, M., Mudan, S. (2016) Two cases of gallbladder metastasis from renal cell carcinoma and review of literature. World Journal of Surgical Oncology, 14. ISSN 1477-7819

Shelley, C., Gore, M., Tan, S., Thomas, K., Eeles, R. (2018) Cervical Spine Fractures in Patients Undergoing Palliative Radiotherapy to the Cervical Spine: Implications for Practice. CLINICAL ONCOLOGY, 30 (7). p. 458. ISSN 0936-6555

Glasspool, R. M., Brown, R., Gore, M. E., Rustin, G. J. S., McNeish, I. A., Wilson, R. H., Pledge, S., Paul, J., Mackean, M., Hall, G. D., Gabra, H., Halford, S. E. R., Walker, J., Appleton, K., Ullah, R., Kaye, S., Scottish Gynaecological Trials, Grp (2014) A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2 '-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. BRITISH JOURNAL OF CANCER, 110 (8). pp. 1923-1929. ISSN 0007-0920

McLachlan, J., Boussios, S., Okines, A., Glaessgen, D., Bodlar, S., Kalaitzaki, R., Taylor, A., Lalondrelle, S., Gore, M., Kaye, S., Banerjee, S. (2017) The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. CLINICAL ONCOLOGY, 29 (3). pp. 153-160. ISSN 0936-6555

Morganstein, D. L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., Larkin, J. (2017) Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. CLINICAL ENDOCRINOLOGY, 86 (4). pp. 614-620. ISSN 0300-0664

Smith, M. J. F., Smith, H. G., Joshi, K., Gore, M., Strauss, D. C., Hayes, A. J., Larkin, J. (2018) The impact of effective systemic therapies on surgery for stage IV melanoma. EUROPEAN JOURNAL OF CANCER, 103. pp. 24-31. ISSN 0959-8049

H

Chau, I., Jones, R., Cunningham, D., Wotherspoon, A., Maisey, N., Norman, A. R., Jain, P., Bishop, L., Horwich, A., Catovsky, D. (2003) Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? BRITISH JOURNAL OF CANCER, 89 (1). pp. 36-42. ISSN 0007-0920

J

Ford, H. E. R., Mitchell, F., Cunningham, D., Farrugia, D. C., Hill, M. E., Rees, C., Calvert, H., Judson, I. R., Jackman, A. L. (2002) Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker to thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-flourouracil and the specific TS inhibitors raltitrexed (tomudex) and ZD93311. CLINICAL CANCER RESEARCH, 8 (1). pp. 103-109. ISSN 1078-0432

Verweij, J., Casali, P. G., Kotasek, D., Le Cesne, A., Reichard, P., Judson, I. R., Issels, R., Oosterom, A. T., Glabbeke, M., Blay, J. Y. (2007) Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005. EUROPEAN JOURNAL OF CANCER, 43 (6). pp. 974-978. ISSN 0959-8049

K

Pemberton, L., Coote, J., Perry, L., Khoo, V. S., Saunders, M. P. (2006) Adjuvant chemoradiotherapy for gastric carcinoma: Dosimetric implications of conventional gastric bed irradiation and toxicity. CLINICAL ONCOLOGY, 18 (9). pp. 663-668. ISSN 0936-6555

Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernandez-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., Rata, M., Koh, D. M., Tunariu, N., Collins, D., Hulkki-Wilson, S., Ragulan, C., Spiteri, I., Moorcraft, S. Y., Chau, I., Rao, S., Watkins, D., Fotiadis, N., Bali, M., Darvish-Damavandi, M., Lote, H., Eltahir, Z., Smyth, E. C., Begum, R., Clarke, P. A., Eltahir, Z., Smyth, E. C., Begum, R., Clarke, P. A., Hahne, J. C., Dowsett, M., de Bono, J., Workman, P., Sadanandam, A., Fassan, M., Sansom, O. J., Eccles, S., Starling, N., Braconi, C., Sottoriva, A., Robinson, S. P., Cunningham, D., Valeri, N. (2018) Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. SCIENCE, 359 (6378). pp. 920-926. ISSN 0036-8075

Tam, H. H., Collins, D. J., Brown, G., Chau, I., Cunningham, D., Leach, M. O., Koh, D. M. (2013) The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis. BRITISH JOURNAL OF RADIOLOGY, 86 (1030). ISSN 0007-1285

L

Martin-Liberal, J., Kordbacheh, T., Larkin, J. (2015) Safety of pembrolizumab for the treatment of melanoma. EXPERT OPINION ON DRUG SAFETY, 14 (6). pp. 957-964. ISSN 1474-0338

Turajlic, S., Xu, H., Litchfield, K., Rowan, A., Horswell, S., Chambers, T., O'Brien, T., Lopez, J. I., Watkins, T. B. K., Nicol, D., Stares, M., Challacombe, B., Hazell, S., Chandra, A., Mitchell, T. J., Au, L., Eichler-Jonsson, C., Jabbar, F., Soultati, A., Chowdhury, S., Rudman, S., Lynch, J., Fernando, A., Stamp, G., Nye, E., Stewart, A., Xing, W., Smith, J. C., Escudero, M., Huffman, A., Matthews, N., Elgar, G., Phillimore, B., Costa, M., Begum, S., Ward, S., Salm, M., Boeing, S., Fisher, R., Spain, L., Navas, C., Gronroos, E., Hobor, S., Sharma, S., Aurangzeb, I., Lall, S., Polson, A., Varia, M., Horsfield, C., Fotiadis, N., Pickering, L., Schwarz, R. F., Silva, B., Herrero, J., Luscombe, N. M., Jamal-Hanjani, M., Rosenthal, R., Birkbak, N. J., Wilson, G. A., Pipek, O., Ribli, D., Krzystanek, M., Csabai, I., Szallasi, Z., Gore, M., McGranahan, N., Van Loo, P., Campbell, P., Larkin, J., Swanton, C., Consortium, T. RACERx Renal (2018) Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. CELL, 173 (3). pp. 595-610. ISSN 0092-8674

Mitchell, T. J., Turajlic, S., Rowan, A., Nicol, D., Farmery, J. H. R., O'Brien, T., Martincorena, I., Tarpey, P., Angelopoulos, N., Yates, L. R., Butler, A. P., Raine, K., Stewart, G. D., Challacombe, B., Fernando, A., Lopez, J. I., Hazell, S., Chandra, A., Chowdhury, S., Rudman, S., Soultati, A., Stamp, G., Fotiadis, N., Pickering, L., Au, L., Spain, L., Lynch, J., Stares, M., Teague, J., Maura, F., Wedge, D. C., Horswell, S., Chambers, T., Litchfield, K., Xu, H., Stewart, A., Elaidi, R., Oudard, S., McGranahan, N., Csabai, I., Gore, M., Futreal, P. A., Larkin, J., Lynch, A. G., Szallasi, Z., Swanton, C., Campbell, P. J., Consortium, T. RACERx Renal (2018) Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. CELL, 173 (3). pp. 611-623. ISSN 0092-8674

Koh, D. M., Brown, G., Riddell, A. M., Scurr, E., Collins, D. J., Allen, S. D., Chau, I., Cunningham, D., Desouza, N. M., Leach, M. O., Husband, J. E. (2008) Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. EUROPEAN RADIOLOGY, 18 (5). pp. 903-910. ISSN 0938-7994

Chong, I. Y., Aronson, L., Bryant, H., Gulati, A., Campbell, J., Elliott, R., Pettitt, S., Wilkerson, P., Lambros, M. B., Reis-Filho, J. S., Ramessur, A., Davidson, M., Chau, I., Cunningham, D., Ashworth, A., Lord, C. J. (2018) Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. GUT, 67 (10). ISSN 0017-5749

P

Arias-Mendoza, F., Payne, G. S., Zakian, K., Stubbs, M., O'Connor, O. A., Mojahed, H., Smith, M. R., Schwarz, A. J., Shukla-Dave, A., Howe, F., Poptani, H., Lee, S. C., Pettengel, R., Schuster, S. J., Cunningham, D., Heerschap, A., Glickson, J. D., Griffiths, J. R., Koutcher, J. A., Leach, M. O., Brown, T. R. (2013) Noninvasive Phosphorus Magnetic Resonance Spectroscopic Imaging Predicts Outcome to First-line Chemotherapy in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma. ACADEMIC RADIOLOGY, 20 (9). pp. 1122-1129. ISSN 1076-6332

R

Okines, A. F. C., de Castro, D. G., Cunningham, D., Chau, I., Langley, R. E., Thompson, L. C., Stenning, S. P., Saffery, C., Barbachano, Y., Coxon, F., Middleton, G., Ferry, D., Crosby, T., Madhusudan, S., Wadsley, J., Waters, J., Hall, M., Swinson, D., Robinson, A., Smith, D., Reis, J. S., Waddell, T. S., Puckey, L., Wilson, S. H., Eltahir, Z., Band, M., Wotherspoon, A., Grp, Ncri Upper GI Clinical Studies (2013) Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. EUROPEAN JOURNAL OF CANCER, 49 (9). pp. 2116-2125. ISSN 0959-8049

Okines, A. F. C., Reynolds, A. R., Cunningham, D. (2011) Targeting Angiogenesis in Esophagogastric Adenocarcinoma. ONCOLOGIST, 16 (6). pp. 844-858. ISSN 1083-7159

Frentzas, S., Simoneau, E., Bridgeman, V. L., Vermeulen, P. B., Foo, S., Kostaras, E., Nathan, M. R., Wotherspoon, A., Gao, Z. H., Shi, Y., Van den Eynden, G., Daley, F., Peckitt, C., Tan, X., Salman, A., Lazaris, A., Gazinska, P., Berg, T. J., Eltahir, Z., Ritsma, L., van Rheenen, J., Khashper, A., Brown, G., Nystrom, H., Sund, M., Van Laere, S., Loyer, E., Dirix, L., Cunningham, D., Metrakos, P., Reynolds, A. R. (2016) Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. NATURE MEDICINE, 22 (11). pp. 1294-1302. ISSN 1078-8956

S

Kipps, E., Young, K., Starling, N. (2017) Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy. Therapeutic Advances in Medical Oncology, 9 (3). pp. 159-170. ISSN 1758-8340

Davidson, M., Starling, N. (2016) Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives. Oncotargets and Therapy, 9. pp. 7235-7245. ISSN 1178-6930

Almhanna, K., Wright, D., Mercade, T. M., Laethem, J. L., Gracian, A. C., Guillen-Ponce, C., Faris, J., Lopez, C. M., Hubner, R. A., Bendell, J., Bols, A., Feliu, J., Starling, N., Enzinger, P., Mahalingham, D., Messersmith, W., Yang, H. Y., Fasanmade, A., Danaee, H., Kalebic, T. (2017) A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. INVESTIGATIONAL NEW DRUGS, 35 (5). pp. 634-641. ISSN 0167-6997

Moorcraft, S. Y., de Castro, D. G., Cunningham, D., Jones, T., Walker, B. A., Peckitt, C., Yuan, L. C., Frampton, M., Begum, R., Eltahir, Z., Wotherspoon, A., Mendes, L. S. T., Wilson, S. H., Gillbanks, A., Baratelli, C., Fotiadis, N., Patel, A., Braconi, C., Valeri, N., Gerlinger, M., Rao, S., Watkins, D., Chau, I., Starling, N. (2018) Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice. ANNALS OF ONCOLOGY, 29 (1). pp. 230-236. ISSN 0923-7534

Davidson, M., Cafferkey, C., Goode, E. F., Kouvelakis, K., Hughes, D., Reguera, P., Kalaitzaki, E., Peckitt, C., Rao, S., Watkins, D., Chau, I., Cunningham, D., Starling, N. (2018) Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients. CLINICAL COLORECTAL CANCER, 17 (3). pp. 223-230. ISSN 1533-0028

Pearson, A., Smyth, E., Babina, I. S., Herrera-Abreu, M. T., Tarazona, N., Peckitt, C., Kilgour, E., Smith, N. R., Geh, C., Rooney, C., Cutts, R., Campbell, J., Ning, J., Fenwick, K., Swain, A., Brown, G., Chua, S., Thomas, A., Johnston, S. R. D., Ajaz, M., Sumpter, K., Gillbanks, A., Watkins, D., Chau, I., Popat, S., Cunningham, D., Turner, N. C. (2016) High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. Cancer Discovery, 6 (8). pp. 838-851. ISSN 2159-8274

Swerdlow, A. J., Higgins, C. D., Smith, P., Cunningham, D., Hancock, B. W., Horwich, A., Hoskin, P. J., Lister, A., Radford, J. A., Rohatiner, A. Z. S., Linch, D. C. (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 99 (3). pp. 206-214. ISSN 0027-8874

Swerdlow, A. J., Higgins, C. D., Smith, P., Cunningham, D., Hancock, B. W., Horwich, A., Hoskin, P. J., Lister, T. A., Radford, J. A., Rohatiner, A. Z. S., Linch, D. C. (2011) Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study. JOURNAL OF CLINICAL ONCOLOGY, 29 (31). pp. 4096-4104. ISSN 0732-183X

Swerdlow, A. J., Cooke, R., Bates, A., Cunningham, D., Falk, S. J., Gilson, D., Hancock, B. W., Harris, S. J., Horwich, A., Hoskin, P. J., Linch, D. C., Lister, A., Lucraft, H. H., Radford, J., Stevens, A. M., Syndikus, I., Williams, M. V., England Wales Hodgkin, Lymphoma (2014) Risk of Premature Menopause After Treatment for Hodgkin's Lymphoma. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 106 (9). ISSN 0027-8874

T

Kontovounisios, C., Tan, E., Pawa, N., Brown, G., Tait, D., Cunningham, D., Rasheed, S., Tekkis, P. (2017) The selection process can improve the outcome in locally advanced and recurrent colorectal cancer: activity and results of a dedicated multidisciplinary colorectal cancer centre. COLORECTAL DISEASE, 19 (4). pp. 331-338. ISSN 1462-8910

V

Fassan, M., Vianello, L., Sacchi, D., Fanelli, G. N., Munari, G., Scarpa, M., Cappellesso, R., Loupakis, F., Lanza, C., Salmaso, R., Mescoli, C., Valeri, N., Agostini, M., D'Angelo, E., Lonardi, S., Pucciarelli, S., Veronese, N., Luchini, C., Rugge, M. (2018) Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. CANCER CELL INTERNATIONAL, 18. ISSN 1475-2867

Tomasello, G., Valeri, N., Ghidini, M., Smyth, E. C., Liguigli, W., Toppo, L., Mattioli, R., Curti, A., Hahne, J. C., Negri, F. M., Panni, S., Ratti, M., Lazzarelli, S., Gerevini, F., Colombi, C., Panni, A., Rovatti, M., Treccani, L., Martinotti, M., Passalacqua, R. (2017) First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. ONCOTARGET, 8 (67). pp. 111795-111806. ISSN 1949-2553

Ghidini, M., Hahne, J. C., Frizziero, M., Tomasello, G., Trevisani, F., Lampis, A., Passalacqua, R., Valeri, N. (2018) MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours. TARGETED ONCOLOGY, 13 (4). pp. 423-436. ISSN 1776-2596

Ratti, M., Lampis, A., Hahne, J. C., Passalacqua, R., Valeri, N. (2018) Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. CMLS-Cellular and Molecular Life Sciences, 75 (22). pp. 4151-4162. ISSN 1420-682X

Smyth, E., Khan, K., Valeri, N. (2018) Translational research and application of basic biology to clinical trial development in GI cancers. ANNALS OF TRANSLATIONAL MEDICINE, 6 (9). ISSN 2305-5839

Davarzani, N., Hutchins, G. G. A., West, N. P., Hewitt, L. C., Nankivell, M., Cunningham, D., Allum, W. H., Smyth, E., Valeri, N., Langley, R. E., Grabsch, H. I. (2018) Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial. HISTOPATHOLOGY, 72 (7). pp. 1180-1188. ISSN 0309-0167

Khan, K., Rata, M., Cunningham, D., Koh, D. M., Tunariu, N., Hahne, J. C., Vlachogiannis, G., Hedayat, S., Marchetti, S., Lampis, A., Damavandi, M. D., Lote, H., Rana, I., Williams, A., Eccles, S. A., Fontana, E., Collins, D., Eltahir, Z., Rao, S., Watkins, D., Starling, N., Thomas, J., Kalaitzaki, E., Fotiadis, N., Begum, R., Bali, M., Rugge, M., Temple, E., Fassan, M., Chau, I., Braconi, C., Valeri, N. (2018) Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. GUT, 67 (8). pp. 1484-1492. ISSN 0017-5749

Lampis, A., Carotenuto, P., Vlachogiannis, G., Cascione, L., Hedayat, S., Burke, R., Clarke, P., Bosma, E., Simbolo, M., Scarpa, A., Yu, S. J., Cole, R., Smyth, E., Mateos, J. F., Begum, R., Hezelova, B., Eltahir, Z., Wotherspoon, A., Fotiadis, N., Bali, M. A., Nepal, C., Khan, K., Stubbs, M., Hahne, J. C., Gasparini, P., Guzzardo, V., Croce, C. M., Eccles, S., Fassan, M., Cunningham, D., Andersen, J. B., Workman, P., Valeri, N., Braconi, C. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. GASTROENTEROLOGY, 154 (4). pp. 1066-1079. ISSN 0016-5085

W

Watson, M., Homewood, J. (2001) Quality of life: a key outcome measure in colorectal cancer? COLORECTAL CANCER, 5. pp. 85-91. ISSN 1364-4831

Maisey, N. R., Norman, A., Watson, M., Allen, M. J., Hill, M. E., Cunningham, D. (2002) Baseline quality of life predicts survival in patients with advanced colorectal cancer. EUROPEAN JOURNAL OF CANCER, 38 (10). pp. 1351-1357. ISSN 0959-8049

Ross, P. J., George, M., Cunningham, D., Di Stefano, F., Andreyev, H. J. N., Workman, P., Clarke, P. A. (2001) Inhibition of kirsten-ras expression in human colorectal cancer using rationally selected kirsten-ras antisense oligonucleotides. MOLECULAR CANCER THERAPEUTICS, 1 (1). pp. 29-41. ISSN 1535-7163

Clarke, P. A., George, M. L., Easdale, S., Cunningham, D., Swift, R. I,. Hill, M. E., Tait, D. M., Workman, P. (2003) Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. CANCER RESEARCH, 63 (20). pp. 6855-6863. ISSN 0008-5472

Carotenuto, P., Fassan, M., Pandolfo, R., Lampis, A., Vicentini, C., Cascione, L., Paulus-Hock, V., Boulter, L., Guest, R., Quagliata, L., Hahne, J. C., Ridgway, R., Jamieson, T., Athineos, D., Veronese, A., Visone, R., Murgia, C., Ferrari, G., Guzzardo, V., Evans, T. R. J., MacLeod, M., Feng, G. J., Dale, T., Negrini, M., Forbes, S. J., Terracciano, L., Scarpa, A., Patel, T., Valeri, N., Workman, P., Sansom, O., Braconi, C. (2017) Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. GUT, 66 (7). pp. 1268-1277. ISSN 0017-5749